var title_f21_45_22224="Choi laryngoscope";
var content_f21_45_22224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choi (double angle) laryngoscope blade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22224=[""].join("\n");
var outline_f21_45_22224=null;
var title_f21_45_22225="Subcutaneous sarcoidosis";
var content_f21_45_22225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcutaneous sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcutaneous sarcoidosis. Multiple indurated nodules are present on the forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22225=[""].join("\n");
var outline_f21_45_22225=null;
var title_f21_45_22226="Mitral stenosis gradients";
var content_f21_45_22226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis gradients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mitral Stenosis. The LV and PCW (left side) is compared with LV and LA pressures (transseptal) to demonstrate differences in mitral gradients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22226=[""].join("\n");
var outline_f21_45_22226=null;
var title_f21_45_22227="Post pneumonectomy CT";
var content_f21_45_22227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural calcification after remote right pneumonectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive parietal pleural calcifications after remote right pneumonectomy. CT shows residual liquid in the vacant, small right hemithorax with circumferential dystrophic calcification of the remaining parietal pleura and extensive cardiomediastinal shift to the right. The adjacent right- sided ribs are sclerotic due to postoperative changes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22227=[""].join("\n");
var outline_f21_45_22227=null;
var title_f21_45_22228="Excoriee des jeunes filles";
var content_f21_45_22228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acne excori&eacute;e des jeunes filles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Multiple excoriations are present on the face.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22228=[""].join("\n");
var outline_f21_45_22228=null;
var title_f21_45_22229="Dacarbazine: Pediatric drug information";
var content_f21_45_22229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dacarbazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"    see \"Dacarbazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/27/43444?source=see_link\">",
"    see \"Dacarbazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dacarbazine for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"      see \"Dacarbazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric solid tumors: 200-470 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 5 days every 21-28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hodgkin's disease: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 15 of treatment course, repeat every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Malignant melanoma: 2-4.5 mg/kg/day for 10 days, repeat in 4 weeks or may use 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days, repeat in 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hodgkin's disease: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days, repeat every 4 weeks",
"     <b>",
"      or",
"     </b>",
"     375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1, repeat in 15 days of each 28-day cycle in combination with other agents",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Reconstitute 100 mg vial with 9.9 mL SWI or 200 mg vial with 19.7 mL SWI, resulting in a concentration of 10 mg/mL; may further dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS and administer by slow IVP over 2-3 minutes or by I.V. infusion over 15-120 minutes at a concentration not to exceed 10 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, aztreonam, doxorubicin liposomal, etoposide phosphate, filgrastim, fludarabine, granisetron, melphalan, ondansetron, paclitaxel, palonosetron, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, cefepime, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&ordm;C to 8&deg;C (36&ordm;F to 46&deg;F); protect from light; reconstituted dacarbazine solution 10 mg/mL is stable for 72 hours when refrigerated or 8 hours at room temperature; dacarbazine solution further diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS is stable for 24 hours when refrigerated or 8 hours at room temperature; drug decomposition has occurred if the solution turns pink; dacarbazine is incompatible with hydrocortisone sodium succinate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of malignant melanoma, Hodgkin's disease (FDA approved in adults); has also been used in the treatment of soft tissue sarcomas (fibrosarcomas, rhabdomyosarcoma), islet cell carcinoma, pheochromocytoma, and medullary carcinoma of the thyroid",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dacarbazine may be confused with procarbazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset: 5-7 days; nadir: 7-10 days; recovery: 21-28 days), leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain on infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent, postmarketing, and/or case reports: Anaphylactic reactions, anemia, diarrhea, eosinophilia, erythema, facial flushing, facial paresthesia, flu-like syndrome (fever, myalgia, malaise), hepatic necrosis, hepatic vein occlusion, liver enzymes increased (transient), paresthesia, photosensitivity, rash, renal functions test abnormalities, taste alteration, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dacarbazine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with bone marrow suppression, renal and/or hepatic impairment; dosage reduction may be necessary in patients with renal or hepatic insufficiency; avoid extravasation of the drug; extravasation may result in tissue damage and severe pain. Administer under the supervision of a physician experienced in cancer chemotherapy. Physician should weigh risk to benefit ratio",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Hematopoietic depression is common",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Leukopenia and thrombocytopenia may be life-threatening; temporary cessation of drug may be required with bone marrow suppression. Hepatotoxicity with hepatocellular necrosis and hepatic vein thrombosis has been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; hepatotoxicity usually occurs with combination chemotherapy, but may occur with dacarbazine alone; may be carcinogenic and/or teratogenic",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; dacarbazine has been reported to cause sterility and is mutagenic and teratogenic in rats.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F156264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2E1 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Moderate): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Strong): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May decrease the serum concentration of Dacarbazine. Sorafenib may also increase the concentration of dacarbazine's active metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5571043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: This agent is carcinogenic and/or teratogenic when used in animals;",
"     </b>",
"     adverse effects have been observed in animal studies. There are no adequate and well-controlled trials in pregnant women; use in pregnancy only if the potential benefit outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, erythrocytes and platelet count; liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkylating agent which is converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide] via the cytochrome P450 system. The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O",
"     <sup>",
"      6",
"     </sup>",
"     , N",
"     <sup>",
"      7",
"     </sup>",
"     guanine positions which lead to DNA double strand breaks and apoptosis. Noncell cycle specific.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes to the liver; very little distribution into CSF with CSF concentrations &sim;14% of plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults: 17 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Minimal, 5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: N-demethylated in the liver by microsomal enzymes; metabolites may also have an antineoplastic effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, biphasic: Initial: 20-40 minutes; terminal: 5 hours (in patients with normal renal/hepatic function)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;30% to 50% of dose excreted in urine by tubular secretion, 15% to 25% is excreted in urine as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/27/43444?source=see_link\">",
"      see \"Dacarbazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Restrict intake of food for 4-6 hours prior to dacarbazine dose to decrease vomiting; flu-like symptoms (ie, malaise, fever, myalgia) may occur 1 week after infusion. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Women of childbearing age should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22229/abstract-text/2006077 /pubmed\" id=\"2006077 \" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finklestein JZ, Albo V, Ertel I, et al, &ldquo;5-(3,3-Dimethyl-l-triazeno) imidazole-4-carboxamide (NSC-45388) in the Treatment of Solid Tumors in Children,&rdquo;",
"      <i>",
"       Cancer Chemother Rep",
"      </i>",
"      , 1975, 59(2 Pt 1):351-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22229/abstract-text/167936/pubmed\" id=\"167936\" target=\"_blank\">",
"        167936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marchesi F, Turriziani M, Tortorelli G, et al, \"Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,\"",
"      <i>",
"       Pharmacol Res",
"      </i>",
"      , 2007, 56(4):275-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22229/abstract-text/17897837/pubmed\" id=\"17897837\" target=\"_blank\">",
"        17897837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mutz ID and Urban CE, &ldquo;Dimethyl-triazeno-imidazole-carboxamide (DTIC) in Combination Chemotherapy for Childhood Neuroblastoma,&rdquo;",
"      <i>",
"       Wien Klin Wochenschr",
"      </i>",
"      , 1978, 90(24):867-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22229/abstract-text/741754/pubmed\" id=\"741754\" target=\"_blank\">",
"        741754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13200 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22229=[""].join("\n");
var outline_f21_45_22229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708693\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156223\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046817\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046809\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156202\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156187\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046821\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156275\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046812\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046820\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156278\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156274\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046824\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046808\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046807\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156264\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156196\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156198\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5571043\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046816\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046806\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046823\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046814\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=related_link\">",
"      Dacarbazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/27/43444?source=related_link\">",
"      Dacarbazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_45_22230="Treatment of stage II seminoma";
var content_f21_45_22230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of stage II seminoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/45/22230/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22230/contributors\">",
"     Clair J Beard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22230/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/45/22230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22230/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/45/22230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22230/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/45/22230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer is the most common solid malignancy affecting males aged 15 to 35 years, although these tumors only account for approximately 1 percent of all cancers in men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/1\">",
"     1",
"    </a>",
"    ]. Germ cell tumors (GCTs), which account for 95 percent of testicular cancers, are one of the most curable solid neoplasms due to treatment advances that began in the late 1970s.",
"   </p>",
"   <p>",
"    GCTs can consist of one histologic pattern or a mix of multiple histologic types. Testicular GCTs are divided into two groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pure seminoma (ie, no nonseminomatous elements), which constitute approximately 60 percent of GCTs [",
"      <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonseminomatous GCTs (NSGCTs), which may include elements of seminoma along with one or more other histologic types.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical stage II disease is defined by the presence of pure seminoma in the orchiectomy specimen and imaging studies of the abdomen and pelvis that show positive regional lymph nodes (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    ). Positive nodes are those that measure at least 10mm on the short axis of cross-sectional imaging. Other potential sites of metastasis, such as the chest, are free of disease. About 15 percent of patients with seminoma have stage II disease at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with stage I seminoma (ie, no lymph node involvement) are increasingly being managed with orchiectomy followed by active surveillance. Approximately 85 percent of these men are cured by orchiectomy and will remain disease-free. Most of those who relapse during surveillance have disease limited to the retroperitoneum; these men are treated like those who initially present with stage II disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"     \"Treatment of stage I seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients who present with stage II seminoma and of those with stage I disease who relapse in regional lymph nodes will be reviewed here. An overview of the approach to testicular germ cell tumors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19858?source=see_link\">",
"     \"Treatment protocols for germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seminomas are highly sensitive to both radiation therapy (RT) and chemotherapy. Successful control of seminoma can be achieved in almost all patients using contemporary treatment techniques. Thus the focus has shifted to minimize treatment-related morbidity.",
"   </p>",
"   <p>",
"    The optimal treatment for men with stage II seminoma depends upon the extent of nodal involvement. Patients with stage II seminoma are divided according to the maximum diameter of involved lymph nodes (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IIA: &le;2 cm",
"     </li>",
"     <li>",
"      Stage IIB: &gt;2 and &le;5 cm",
"     </li>",
"     <li>",
"      Stage IIC: &gt;5 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with stage IIA disease are considered to have nonbulky disease and are generally managed with RT. Those with stage IIC are classified as having bulky disease and managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy. Patients with intermediate-sized lymph nodes (ie, stage IIB) are variably classified and managed with either RT or chemotherapy. These approaches are consistent with current consensus guidelines from the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the Canadian Germ Cell Cancer conference [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19055979\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonbulky (stage IIA/IIB) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for nonbulky (stage",
"    <span class=\"nowrap\">",
"     IIA/IIB)",
"    </span>",
"    seminoma generally consists of RT, with chemotherapy reserved for salvage of patients who subsequently relapse. Contemporary studies in patients with IIA and nonbulky IIB seminoma have yielded five-year disease-free survival rates of 90 percent or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of treatment in men with nonbulky abdominal disease is illustrated by a prospective SWENOTECA study of 1384 men with pure testicular seminoma diagnosed and treated in Sweden and Norway from 2000 to 2006, with follow-up through 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/10\">",
"     10",
"    </a>",
"    ]. This series included 102 patients with clinical stage IIA or IIB disease. The five-year overall and cancer-specific survival rates were 100 percent. There were three relapses in the 29 patients treated with RT, all of whom were salvaged with chemotherapy. These relapses may have been due to the somewhat lower than standard dose of radiation (27 Gy) used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard RT following orchiectomy for patients with nonbulky stage II disease consists of low-dose treatment to the paraaortic lymph nodes and superior ipsilateral pelvis followed by a small optional boost to the involved nodal areas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/11\">",
"     11",
"    </a>",
"    ]. The total radiation dose to areas of gross adenopathy is 25 to 35 Gy. The scrotum, inguinal lymph nodes, and mediastinum are not routinely treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H261198349#H261198349\">",
"     \"Treatment of stage I seminoma\", section on 'Adjuvant radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adverse effects of RT for stage II seminoma are similar to those described following treatment of stage I disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H77784158#H77784158\">",
"     \"Treatment of stage I seminoma\", section on 'Treatment-related toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about the long-term toxicity of RT prompted consideration of chemotherapy as a less toxic alternative to RT for patients with stage II seminoma. Although single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is successfully used as an adjuvant for men with stage I seminoma who are not candidates for active surveillance, this approach is not been as effective for those with stage II disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H77783389#H77783389\">",
"     \"Treatment of stage I seminoma\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The German Testicular Cancer Study Group studied three to four cycles of single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (dosed at an area under the concentration x time curve [AUC] of 7) in patients with stage",
"    <span class=\"nowrap\">",
"     IIA/IIB",
"    </span>",
"    seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/12\">",
"     12",
"    </a>",
"    ]. A complete response was achieved in 88 of 108 cases (81 percent). In five of the cases that did not achieve a complete response, viable tumor was identified in the surgical resection specimen of residual disease. Furthermore, 14 patients (13 percent) who initially achieved a complete response relapsed and required salvage therapy.",
"   </p>",
"   <p>",
"    Combination chemotherapy may be more effective, but is associated with increased toxicity. Treatment with four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    or three cycles of cisplatin, etoposide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    was evaluated in 72 patients with stage IIA or IIB seminoma in a trial from the Spanish Germ Cell Cancer Group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/13\">",
"     13",
"    </a>",
"    ]. There were no relapses in the 18 patients with IIA disease, and six (11 percent) in those with IIB disease. Overall survival rate at five years was 95 percent, with only one death secondary to progressive seminoma.",
"   </p>",
"   <p>",
"    The side effects associated with combination chemotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bulky (stage IIB/IIC) seminoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bulky (stage",
"    <span class=\"nowrap\">",
"     IIB/IIC)",
"    </span>",
"    seminoma are generally managed with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy regimen. Although RT can successfully treat the majority of patients with bulky stage II disease, the incidence of relapse and the associated need for salvage chemotherapy has made chemotherapy the preferred treatment option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Good-risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seminoma is a highly sensitive to chemotherapy, and even men with advanced seminoma are classified as having good-risk disease by the International Germ Cell Cancer Collaborative Group (IGCCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/14\">",
"     14",
"    </a>",
"    ]. Multiple clinical trials have documented the favorable outcome in this population, with 90 percent of patients achieving long-term, relapse free survival. Typical regimens include three cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or four cycles of etoposide plus cisplatin. The clinical trials supporting these regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of combination chemotherapy in men treated with chemotherapy is illustrated by a series of 42 men with stage IIC seminoma who were treated with four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    between 2000 and 2006 as part of the SWENOTECA study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/10\">",
"     10",
"    </a>",
"    ]. The five-year cancer-specific and overall survival rates were 97.6 and 95.1 percent, respectively; there were six relapses and three deaths due to progressive cancer. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Nonbulky (stage IIA/IIB) disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The long-term results after chemotherapy appear to be better for patients with bulky disease who have had limited infradiaphragmatic-only radiation therapy as compared with those who were irradiated more extensively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19056100\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Post therapy residual masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with stage II seminoma have residual masses detected by imaging following treatment, including up to 80 percent of those managed with chemotherapy for bulky disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Many of these masses do not contain viable tumor, and approximately one-half of these will disappear during surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/19\">",
"     19",
"    </a>",
"    ]. The presence of such masses can pose a difficult problem in assessing the adequacy of initial treatment, since these do not necessarily require resection.",
"   </p>",
"   <p>",
"    Early studies reported that there was a higher incidence of viable seminoma or local disease progression in cases where the residual mass was &ge;3 cm on CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, this criterion does not detect all cases with viable tumor in smaller nodes, and many cases with larger residual masses are comprised exclusively of necrotic tissue.",
"   </p>",
"   <p>",
"    Imaging with PET scanning appears to be a better indicator of the presence of viable residual tumor tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The most extensive data on the use of PET come from the multicenter SEMPET study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/22\">",
"     22",
"    </a>",
"    ]. In that study, 56 PET scans were performed in 51 patients with CT-documented residual masses 1 to 11 cm after chemotherapy for bulky seminoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall sensitivity of PET was superior to that with a CT using a size criterion of 3 cm (80 versus 70 percent), as was the specificity (100 versus 74 percent).",
"     </li>",
"     <li>",
"      In the 19 patients with a residual lesion &gt;3 cm, PET detected all seven cases that either had tumor documented at resection or subsequently relapsed, while accurately predicting the absence of tumor in the remaining 12 cases.",
"     </li>",
"     <li>",
"      In the 37 patients with a residual lesion &le;3 cm, PET detected one of three cases that contained tumor, and accurately predicted the absence of tumor in 34 of 36 cases without disease. There were no false positives in any of the cases where tumor was not documented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elective irradiation in patients with a residual mass and normal serum tumor markers does not appear to improve outcome. In a nonrandomized series of 174 men with seminoma who had residual masses following chemotherapy, one-half received elective post chemotherapy radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/24\">",
"     24",
"    </a>",
"    ]. The use of elective RT was not associated with an improved progression-free survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pure seminoma with elevated tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of men with seminoma have elevations in serum beta human chorionic gonadotropin (beta-hCG). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H4#H4\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Seminomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although once considered a marker of poor prognosis in patients with pure seminoma, elevated serum beta-hCG appears to reflect higher tumor volume but not necessarily metastatic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Some series suggest that extreme elevations in beta hCG are associated with a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Consideration should be given to primary chemotherapy in the unusual patient with extremely elevated beta-hCG levels (&gt;50 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     METASTATIC SEMINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of men with advanced or recurrent seminoma are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Good-risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy may have a role in the management of men with metastases of seminoma beyond the retroperitoneum. For patients with limited sites of metastatic disease outside of the retroperitoneum, the exquisite sensitivity of seminoma to radiation therapy has permitted successful salvage with radiation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22230/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage II seminoma, either at presentation or at relapse following treatment for stage I disease, is a highly curable malignancy. Patients are managed with radiation therapy (RT) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy depending upon the extent of retroperitoneal involvement (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with nonbulky stage",
"      <span class=\"nowrap\">",
"       IIA/IIB",
"      </span>",
"      seminoma, we suggest low-dose RT to the paraaortic lymph nodes and superior ipsilateral pelvis followed by a small boost to the involved nodal areas rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy is a reasonable alternative for patients in whom RT is not feasible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonbulky (stage IIA/IIB) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with bulky stage",
"      <span class=\"nowrap\">",
"       IIB/IIC",
"      </span>",
"      seminoma, we recommend combination chemotherapy with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimen rather than RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Widely used regimens in this setting include three cycles of cisplatin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      (BEP) (",
"      <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"       table 3",
"      </a>",
"      ) or four cycles of etoposide platinum (EP). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bulky (stage IIB/IIC) seminoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For men with residual retroperitoneal masses and normal tumor markers following chemotherapy, we suggest that treatment decisions (observation versus treatment) be based upon the results of PET scan, rather than the size of the residual mass (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Post therapy residual masses'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/2\">",
"      Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007; 64:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/3\">",
"      Warde P, Gospodarowicz M. Evolving concepts in stage I seminoma. BJU Int 2009; 104:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/4\">",
"      Kollmannsberger C, Tyldesley S, Moore C, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011; 22:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/5\">",
"      Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/6\">",
"      Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010; 4:e19.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network guidelines available online at: file://www.nccn.org/professionals/physician_gls/f_guidelines.asp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/8\">",
"      Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/9\">",
"      Chung PW, Gospodarowicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 2004; 45:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/10\">",
"      Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 2011; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/11\">",
"      Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/12\">",
"      Krege S, Boergermann C, Baschek R, et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006; 17:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/13\">",
"      Garcia-del-Muro X, Maroto P, Gum&agrave; J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008; 26:5416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/14\">",
"      International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/15\">",
"      Foss&aring; SD, Borge L, Aass N, et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987; 5:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/16\">",
"      Loehrer PJ Sr, Birch R, Williams SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987; 5:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/17\">",
"      Abratt RP, McAdam GL, Pontin AR, et al. Primary chemotherapy for stage 2 testis cancer. S Afr J Surg 1997; 35:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/18\">",
"      Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985; 52:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/19\">",
"      Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/20\">",
"      Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/21\">",
"      De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19:3740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/22\">",
"      De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/23\">",
"      Rioja J, Rodr&iacute;guez-Fraile M, Lima-Favaretto R, et al. Role of positron emission tomography in urological oncology. BJU Int 2010; 106:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/24\">",
"      Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997; 33:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/25\">",
"      Hori K, Uematsu K, Yasoshima H, et al. Testicular seminoma with human chorionic gonadotropin production. Pathol Int 1997; 47:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/26\">",
"      Mirimanoff RO, Sinzig M, Kr&uuml;ger M, et al. Prognosis of human chorionic gonadotropin-producing seminoma treated by postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1993; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/27\">",
"      Weissbach L, Bussar-Maatz R, L&ouml;hrs U, et al. Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 1999; 36:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/28\">",
"      Motzer RJ, Bosl GJ, Geller NL, et al. Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med 1988; 108:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/29\">",
"      Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/30\">",
"      Herman JG, Sturgeon J, Gospodarowicz M, et al. A prospective clinical trial for testicular seminoma and serum markers. Am J Clin Oncol 1983; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/31\">",
"      Oliver RT, Lore S, Ong J. Alternatives to radiotherapy in the management of seminoma. Br J Urol 1990; 65:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/32\">",
"      Willan BD, McGowan DG. Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 1985; 11:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/33\">",
"      Slawson RG. Radiation therapy for germinal tumors of the testes. Cancer 1978; 42:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/34\">",
"      Lindeman GJ, Tiver KW. Management of testicular seminoma at Westmead Hospital from 1980 to 87. Aust N Z J Surg 1991; 61:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22230/abstract/35\">",
"      Mackey JR, Venner P. Seminoma with isolated central nervous system relapse, and salvage with craniospinal irradiation. Urology 1998; 51:1043.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2990 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-118.195.65.248-F33F7FC12B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22230=[""].join("\n");
var outline_f21_45_22230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19055979\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonbulky (stage IIA/IIB) disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bulky (stage IIB/IIC) seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19056100\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Post therapy residual masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pure seminoma with elevated tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      METASTATIC SEMINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 1\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 2\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 3\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=related_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19858?source=related_link\">",
"      Treatment protocols for germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_45_22231="Pantoprazole: Pediatric drug information";
var content_f21_45_22231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pantoprazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"    see \"Pantoprazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/40/13957?source=see_link\">",
"    see \"Pantoprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protonix&reg;;",
"     </li>",
"     <li>",
"      Protonix&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pantoprazole&reg;;",
"     </li>",
"     <li>",
"      Ava-Pantoprazole;",
"     </li>",
"     <li>",
"      CO Pantoprazole;",
"     </li>",
"     <li>",
"      Mylan-Pantoprazole;",
"     </li>",
"     <li>",
"      Pantoloc&reg;;",
"     </li>",
"     <li>",
"      Pantoprazole for Injection;",
"     </li>",
"     <li>",
"      Panto&trade; I.V.;",
"     </li>",
"     <li>",
"      PMS-Pantoprazole;",
"     </li>",
"     <li>",
"      Q-Pantoprazole;",
"     </li>",
"     <li>",
"      RAN&trade;-Pantoprazole;",
"     </li>",
"     <li>",
"      ratio-Pantoprazole;",
"     </li>",
"     <li>",
"      Riva-Pantoprazole;",
"     </li>",
"     <li>",
"      Sandoz-Pantoprazole;",
"     </li>",
"     <li>",
"      Tecta&reg;;",
"     </li>",
"     <li>",
"      Teva-Pantoprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastric Acid Secretion Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Proton Pump Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"      see \"Pantoprazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. therapy should be discontinued as soon as the patient tolerates oral therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Erosive esophagitis associated with GERD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Oral: Limited data; 20 mg once daily (0.5-1 mg/kg/day) was used in 15 children, 6-13 years of age (20-40 kg) for 28 days (Madrazo-De La Garza, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Treatment and maintenance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:  40 mg/day for up to 8 weeks; in mild GERD, 20 mg/day has been effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.:  40 mg/day for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypersecretory conditions (including Zollinger-Ellison syndrome): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 40 mg twice daily; adjust dose based on patient response; doses up to 240 mg/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 80 mg twice daily; adjust dosage to maintain acid output below 10 mEq/hour; doses up to 80 mg every 8 hours have been used; doses &gt;240 mg/day or treatment duration &gt;6 days have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunctive therapy of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (in combination with antibiotic therapy): Adults: Oral: 40 mg once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal or hepatic Impairment:",
"     </b>",
"     No dosage adjustment needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, delayed release, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protonix&reg;: 40 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protonix&reg; I.V.: 40 mg [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protonix&reg;: 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes granules for suspension",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15386979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Protonix&reg; granules for oral suspension, delayed release tablets:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM324058.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM324058.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Reconstitute powder for injection with 10 mL NS; further dilute in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or LR to a final concentration 0.4-0.8 mg/mL; infuse over 15 minutes at a rate not to exceed 7 mL/minute; for more rapid infusion, dilute reconstituted solution to a final concentration of 4 mg/mL and infuse over 2 minutes; not for I.M. or SubQ use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer tablets without regard to food; tablet should be swallowed whole, do not chew or crush; may be administered with antacids. Protonix&reg; delayed-release suspension should not be crushed or chewed and should be administered 30 minutes before a meal. Administer in 5 mL apple juice, stir for 5 seconds and swallow immediately.  May administer in 1 teaspoonful of applesauce, swallow within 10 minutes of preparation. Do not adminster in water, other liquids, or foods. For nasogastric administration, empty granules into barrel of syringe, add 10 mL apple juice; may rinse syringe with additional apple juice to prevent granules from remaining in syringe.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F206292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetazolamide, alprostadil, aminophylline, ampicillin, anidulafungin, cefazolin, dimenhydrinate, dopamine, doripenem, furosemide, ketorolac, penicillin G potassium, potassium chloride, procainamide, telavancin, ticarcillin/clavulanate, vasopressin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amikacin, amiodarone, amphotericin B, atropine, caffeine citrate, cefotaxime, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, ciprofloxacin, clindamycin, cloxacillin, cyclosporine, dexamethasone sodium phosphate, diazepam, digoxin, diphenhydramine, enalaprilat, esmolol, estrogens (conjugated), fluconazole, hydralazine, hydrocortisone sodium succinate, hydromorphone, indomethacin, isoproterenol, labetalol, levofloxacin, lidocaine, lorazepam, mannitol, meropenem, metoclopramide, moxifloxacin, multiple vitamins, naloxone, nitroprusside, norepinephrine, oxytocin, pancuronium, phenobarbital, piperacillin/tazobactam, potassium phosphate, prochlorperazine edisylate, propofol, propranolol, ranitidine,  thiopental, tobramycin, trimethoprim/sulfamethoxazole, vecuronium, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Calcium chloride, calcium gluconate, caspofungin, cefazolin, ceftriaxone, dimenhydrinate, dobutamine, dopamine, epinephrine, fentanyl, furosemide, gentamicin, heparin, insulin (regular), magnesium sulfate, meperidine, methylprednisolone sodium succinate, metronidazole, midazolam, morphine, nitroglycerin, norepinephrine, octreotide, phenytoin, sodium bicarbonate, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Acetazolamide, alprostadil, aminophylline, ampicillin, penicillin G sodium, piperacillin, potassium chloride, procainamide, ticarcillin/clavulanate, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amikacin, amiodarone, amphotericin B, atropine, caffeine citrate, calcium chloride, calcium gluconate, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, chlorpromazine, ciprofloxacin, clindamycin, cloxacillin, cyclosporine, dexamethasone sodium phosphate, diazepam, digoxin, dimenhydrinate, diphenhydramine, dobutamine, dopamine, enalaprilat, epinephrine, estrogens (conjugated), fentanyl, fluconazole, furosemide, gentamicin, heparin, hydralazine, hydrocortisone sodium succinate, hydromorphone, indomethacin, insulin (regular), isoproterenol, labetalol, lidocaine, lorazepam, magnesium sulfate, meperidine, meropenem, methylprednisolone sodium succinate, metoclopramide, midazolam, morphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxytocin, pancuronium, phenobarbital, phenytoin, piperacillin/tazobactam, potassium phosphate, prochlorperazine edisylate, propranolol, ranitidine, sodium bicarbonate, thiopental, tobramycin, trimethoprim/sulfamethoxazole, vecuronium, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; store tablets at room temperature; refrigerate powder for injection (36&deg;F to 46&deg;F). Reconstituted injection is stable at room temperature for 24 hours; do not freeze; after further dilution with I.V. fluid, the solution is stable at room temperature for 24 hours. Neither the reconstituted solution or diluted solution need be protected from light. Pantoprazole stability is a function of pH; it is rapidly degraded in acidic media, but has acceptable stability under alkaline conditions. Each tablet of pantoprazole is enteric coated to prevent degradation by gastric acidity.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Treatment and maintenance of healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD); treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome; adjunctive therapy of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Short-term treatment (7-10 days) of patients with GERD with a history of erosive esophagitis; an alternative to oral therapy in patients who are unable to continue taking oral pantoprazole; treatment of pathological hypersecretory conditions associated with Zollinger-Ellison syndrome or other GI hypersecretory disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pantoprazole may be confused with ARIPiprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Protonix&reg; may be confused with Lotronex&reg;, Lovenox&reg;, protamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vials containing Protonix&reg; I.V. for injection are not recommended for use with spiked I.V. system adaptors. Nurses and pharmacists have reported breakage of the glass vials during attempts to connect spiked I.V. system adaptors, which may potentially result in injury to healthcare professionals.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Protonix [U.S., Canada] may be confused with Pretanix brand name for indapamide [Hungary]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Cardiovascular: Facial  edema, generalized edema",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Central nervous system: Depression, dizziness, fever, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Photosensitivity, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, flatulence, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Urinary frequency, UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Hepatitis, liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reaction (thrombophlebitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, CPK increased, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Albuminuria, alkaline phosphatase increased, anaphylaxis (including anaphylactic shock), anemia, angioedema, angina pectoris, aphthous stomatitis, arrhythmia, asthma exacerbation, atrial fibrillation/flutter, atrophic gastritis, biliary pain, bone pain, breast pain, bursitis, cataract, CHF, cholecystitis, cholelithiasis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associate diarrhea (CDAD), colitis, contact dermatitis, creatinine increased, cystitis, deafness, dehydration, diabetes mellitus, diplopia, duodenitis, dysarthria, dysmenorrhea, dysphagia, dysuria, ecchymosis, ECG abnormality, eosinophilia, epididymitis, epistaxis, erythema multiforme, esophagitis, extraocular palsy, fatigue, fracture, fungal dermatitis, gastrointestinal carcinoma, gastrointestinal hemorrhage, gastrointestinal moniliasis, GGT increased, gingivitis, glaucoma, glossitis, glycosuria, goiter, gout, hallucinations, hematemesis, hematuria, hemorrhage, hepatic failure, hernia, hyperbilirubinemia, hyperesthesia, hyper-/hypotension, hyperkinesia, hyperuricemia, hypokinesia, hypomagnesemia, hyponatremia, impotence, interstitial nephritis, jaundice, kidney calculus, kidney pain,  leukocytosis, lichenoid dermatitis, maculopapular rash, melena, mouth ulceration, myocardial infarction, myocardial ischemia, neoplasm, neuralgia, neuritis, optic neuropathy (including anterior ischemic), palpitation, pancreatitis, pancytopenia, paresthesia, periodontitis, pneumonia, pyelonephritis, rectal hemorrhage, retinal vascular disorder, rhabdomyolysis, scrotal edema, seizure, Stevens-Johnson syndrome, stomach ulcer, stomatitis, syncope, tachycardia, tenosynovitis, thrombosis, tinnitus, tongue discoloration, toxic epidermal necrolysis, tremor, urethritis, vision abnormal",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pantoprazole, substituted benzimidazole proton pump inhibitors (eg, esomeprazole, omeprazole, lansoprazole), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term treatment (&gt;3 years) may lead to malabsorption of cyanocobalamin (vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     ) caused by hypo or achlorhydria. Injection contains edetate sodium (EDTA); EDTA is a potent chelator of metal ions, particularly zinc; use with caution in patients prone to zinc deficiency or receiving other EDTA-containing products. Zinc supplementation may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In long-term (2-year) studies in rodents, pantoprazole was carcinogenic and caused rare types of gastrointestinal tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to pantoprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Use of gastric acid inhibitors including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). Atrophic gastritis has been reported in gastric biopsies from patients treated long-term with pantoprazole, particularly in patients who were",
"     <i>",
"      H. pylori",
"     </i>",
"     positive. An increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy; patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk. Hypomagnesemia has been reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy), and may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of pantoprazole may be necessary; magnesium concentrations typically return to normal within 1 week of stopping. With I.V. formulation anaphylaxis has been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C19 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric acid secretion by inhibiting the parietal cell membrane enzyme (H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     )-ATPase or proton pump; demonstrates antimicrobial activity against",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acid secretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: I.V.: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral, I.V.: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 11-23.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive liver metabolism; no evidence of active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &sim;77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 1 hour; prolonged half-life (3.5-10 hours) in slow metabolizers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal: 71% (as metabolites); biliary/fecal: 18%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Adults: 7.6-14 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not appreciably removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/40/13957?source=see_link\">",
"      see \"Pantoprazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; do not chew or crush tablets",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F206215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL pantoprazole oral suspension may be made with pantoprazole tablets, sterile water, and sodium bicarbonate powder. Remove the Protonix&reg; imprint from twenty 40 mg tablets with a paper towel dampened with ethanol (improves the look of product). Let tablets air dry. Crush the tablets in a mortar and reduce to a fine powder. Transfer to a 600 mL beaker, and add 340 mL sterile water. Place beaker on a magnetic stirrer. Add 16.8 g of sodium bicarbonate powder and stir for about 20 minutes until the tablet remnants have disintegrated. While stirring, add another 16.8 g of sodium bicarbonate powder and stir for about 5 minutes until powder has dissolved. Add enough sterile water for irrigation to bring the final volume to 400 mL. Mix well. Transfer to amber-colored bottle. Label \"shake well\" and \"refrigerate\". Stable for 62 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Dentinger PJ, Swenson CF, and Anaizi NH, &ldquo;Stability of Pantoprazole in an Extemporaneously Compounded Oral Liquid,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2002, 59(10):953-6.",
"     <span class=\"pubmed-id\">",
"      12040734",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22231/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Madrazo-De La Garza A, Dibildox M, Vargas A, et al, &ldquo;Efficacy and Safety of Oral Pantoprazole 20 mg Given Once Daily for Reflux Esophagitis in Children,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2003, 36(2):261-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22231/abstract-text/ 12548064 /pubmed\" id=\" 12548064 \" target=\"_blank\">",
"        12548064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12677 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22231=[""].join("\n");
var outline_f21_45_22231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572471\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060918\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060911\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206211\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206195\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15386979\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060921\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206292\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060915\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060920\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206294\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206290\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060926\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060910\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060909\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206277\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206204\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206207\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206220\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060908\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060924\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060925\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060917\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206215\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12677\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12677|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=related_link\">",
"      Pantoprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/40/13957?source=related_link\">",
"      Pantoprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_45_22232="Microcytic hypochromic anemia";
var content_f21_45_22232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microcytic hypochromic red cells in iron deficiency anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear from a patient with iron deficiency shows pale small red cells with just a scant rim of pink hemoglobin; occasional \"pencil\" shaped cells are also present. Normal red cells are similar in size to the nucleus of a small lymphocyte (arrow); thus, many microcytic cells are present in this smear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22232=[""].join("\n");
var outline_f21_45_22232=null;
var title_f21_45_22233="Venlafaxine: Drug information";
var content_f21_45_22233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Venlafaxine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=see_link\">",
"    see \"Venlafaxine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/18/19752?source=see_link\">",
"    see \"Venlafaxine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5710003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Effexor XR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Venlafaxine XR;",
"     </li>",
"     <li>",
"      Effexor XR&reg;;",
"     </li>",
"     <li>",
"      GD-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Mylan-Venlafaxine XR;",
"     </li>",
"     <li>",
"      PMS-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Ran-Venlafaxine XR;",
"     </li>",
"     <li>",
"      ratio-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Riva-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Sandoz-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Teva-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Venlafaxine XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate-release tablets:",
"     </i>",
"     Initial: 75 mg/day, administered in 2 or 3 divided doses; may increase in &le;75 mg/day increments at intervals of &ge;4 days as tolerated (maximum daily dose: 225-375 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended-release capsules or tablets:",
"     </i>",
"     Initial: 37.5-75 mg once daily; in patients who are initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4-7 days; dose may then be increased by &le;75 mg/day increments at intervals of &ge;4 days as tolerated (maximum daily dose: 225 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Generalized anxiety disorder:",
"     </b>",
"     Oral:",
"     <i>",
"      Extended-release capsules:",
"     </i>",
"     Initial: 37.5-75 mg once daily; in patients who are initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4-7 days; may then be increased by &le;75 mg/day increments at intervals of &ge;4 days as tolerated (maximum daily dose: 225 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"     Oral:",
"     <i>",
"      Extended-release capsules:",
"     </i>",
"     Initial: 37.5 mg once daily for 1 week; may increase to 75 mg once daily after 7 days, may then be increased by &le;75 mg/day increments at intervals of &ge;7 days (maximum daily dose: 225 mg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Social anxiety disorder:",
"     </b>",
"     Oral:",
"     <i>",
"      Extended-release capsules or tablets:",
"     </i>",
"     75 mg once daily (maximum daily dose: 75 mg); no evidence that doses &gt;75 mg/day offer any additional benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder (unlabeled use):",
"     </b>",
"     Oral: Titrate to usual dosage range of 150-300 mg/day; however, doses up to 375 mg/day have been used; response may be seen in 4 weeks (Phelps, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuropathic pain (unlabeled use):",
"     </b>",
"     Oral: Dosages evaluated varied considerably based on etiology of chronic pain, but efficacy has been shown for many conditions in the range of 75-225 mg/day; onset of relief may occur in 1-2 weeks, or take up to 6 weeks for full benefit (Grothe, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Diabetic neuropathy (unlabeled use):",
"     </i>",
"     Oral: 75-225 mg/day (Bril, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hot flashes (unlabeled use):",
"     </b>",
"     Oral: Doses of 37.5-75 mg/day have demonstrated significant improvement of vasomotor symptoms after 4-8 weeks of treatment; in one study, doses &gt;75 mg/day offered no additional benefit (Evans, 2005; Loprinzi, 2000); however, higher doses (225 mg/day) may be beneficial in patients with perimenopausal depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Attention-deficit disorder (unlabeled use):",
"     </b>",
"     Oral: Initial: Doses vary between 18.75 to 75 mg/day; may increase after 4 weeks to 150 mg/day; if tolerated, doses up to 225 mg/day have been used (Maidment, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     Oral:",
"     <i>",
"      Extended release formulation:",
"     </i>",
"     37.5-300 mg/day (Bandelow, 2008; Benedek, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When discontinuing this medication after more than 1 week of treatment, it is generally recommended that the dose be tapered. If venlafaxine is used for 6 weeks or longer, the dose should be tapered over 2 weeks when discontinuing its use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of venlafaxine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 7 days to elapse between discontinuing venlafaxine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate venlafaxine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving venlafaxine and potential benefits outweigh potential risks, discontinue venlafaxine promptly and administer linezolid or I.V. methylene blue. Monitor for SS for 7 days or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume venlafaxine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2237702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/18/19752?source=see_link\">",
"      see \"Venlafaxine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder (unlabeled use; Olvera, 1996):",
"     </b>",
"     Children and Adolescents: Oral: Initial: 12.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &lt;40 kg: Increase by 12.5 mg/week to maximum of 50 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;40 kg: Increase by 25 mg/week to maximum of 75 mg/day in 3 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mean dose: 60 mg or 1.4 mg/kg administered in 2-3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific recommendations for elderly, but may be best to start lower at 25-50 mg twice daily and increase as tolerated by 25 mg/dose. Extended-release formulation: 37.5 mg once daily, increase by 37.5 mg every 4-7 days as tolerated",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F233769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     GFR: 10-70 mL/minute: Reduce total daily dose by 25% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Reduce total daily dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Mild-to-moderate hepatic impairment: Reduce total daily dose by 50%; further reductions may be necessary in some patients",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 37.5 mg, 75 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Effexor XR&reg;: 37.5 mg, 75 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 37.5 mg, 75 mg, 150 mg, 225 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088586.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088586.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended-release formulations: Swallow capsule or tablet whole; do not crush or chew. Contents of capsule may be sprinkled on a spoonful of applesauce and swallowed immediately without chewing; followed with a glass of water to ensure complete swallowing of the pellets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder, generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F233798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obsessive-compulsive disorder (OCD); hot flashes; neuropathic pain (including diabetic neuropathy); attention-deficit/hyperactivity disorder (ADHD); post-traumatic stress disorder (PTSD); migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Effexor&reg; may be confused with Effexor XR&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Actual frequency may be dependent upon formulation and/or indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (25% to 38%), somnolence (12% to 26%), dizziness (11% to 24%), insomnia (15% to 24%), nervousness (6% to 21%), anxiety (2% to 11%),",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (21% to 58%), xerostomia (12% to 22%), anorexia (8% to 17%), constipation (8% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal ejaculation/orgasm (2% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (7% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (2% to 6%), hypertension (dose related; 3% in patients receiving &lt;100 mg/day, up to 13% in patients receiving &gt;300 mg/day), palpitation (3%), tachycardia (2%), chest pain (2%), orthostatic hypotension (1%), edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Yawning (3% to 8%), abnormal dreams (3% to 7%), chills (2% to 7%), agitation (2% to 5%), confusion (2%), abnormal thinking (2%), depersonalization (1%), depression (1% to 3%), fever, migraine, amnesia, hypoesthesia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3%), pruritus (1%), bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (2% to 8%), hypercholesterolemia (5%), triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8%), diarrhea (8%), vomiting (3% to 8%), dyspepsia (5% to 7%), weight loss (1% to 6%), flatulence (3% to 4%), taste perversion (2%), appetite increased, belching, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (4% to 6%), urinary frequency (3%), urination impaired (2%), urinary retention (1%), metrorrhagia, prostatic disorder, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (1% to 10%), hypertonia (3%), paresthesia (2% to 3%), twitching (1% to 3%), arthralgia, neck pain, trismus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Accommodation abnormal (6% to 9%), abnormal or blurred vision (4% to 6%), mydriasis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (7%), sinusitis (2%), bronchitis, cough increased, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (6%), flu-like syndrome (2%), trauma (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylaxis, anemia, aneurysm, angina pectoris, angioedema, anuria, aplastic anemia, appendicitis, arrhythmia (including atrial and ventricular tachycardia, fibrillation, and torsade de pointes), arteritis, asthma, ataxia, atelectasis, atrioventricular block, bacteremia, balance/coordination impaired, basophilia, bigeminy, biliary pain, bilirubinemia, bleeding time increased, bradycardia, bradykinesia, BUN increased, bundle branch block, carcinoma, cardiac arrest, cardiovascular disorder (mitral valve and circulatory disturbance), cataract, catatonia, cellulitis, cerebral ischemia, cholelithiasis, congestive heart failure, coronary artery disease, CPK increased, creatinine increased, crystalluria, cyanosis, deafness, DVT, dehydration, delusions, dementia, diabetes mellitus, dystonia, ECG abnormalities (including QT prolongation), embolus, eosinophilia, erythema multiforme, exfoliative dermatitis, extrapyramidal symptoms, extrasystoles, facial paralysis, fasciitis, fatty liver, gastrointestinal ulcer, glaucoma, glycosuria, granuloma, Guillain-Barr&eacute; syndrome, hematemesis, hematoma, hemorrhage (eye, GI, mucocutaneous, rectal), hepatic necrosis, hepatic failure, hepatitis, homicidal ideation, hostility, hyperacusis, hypercalcinuria, hyperchlorhydria, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hypophosphatemia, hyper-/hypothyroidism, hyperuricemia, hypocholesteremia, hyponatremia, hypoproteinemia, hypotension, interstitial lung disease (including eosinophilic pneumonia), intestinal obstruction, jaundice, kidney function abnormal, larynx edema, leukocytosis, leukoderma, leukopenia, liver enzymes increased, loss of consciousness, lymphadenopathy, lymphocytosis, maculopapular rash, menstrual abnormalities, MI, miliaria, moniliasis, multiple myeloma, myasthenia, myoclonus, myopathy, neck rigidity, neuroleptic malignant-like syndrome, neuropathy, neutropenia, osteoporosis, pancreatitis, pancytopenia, peripheral vascular disorder, pleurisy, pneumonia, pyelonephritis, pyuria, renal failure, rhabdomyolysis, rheumatoid arthritis, seizure, serotonin syndrome, SIADH, skin atrophy, Stevens-Johnson syndrome, suicidal ideation (reported at a frequency up to 2% in children/adolescents with major depressive disorder), suicide attempt, syncope, tendon rupture, thrombocythemia, thrombocytopenia, tongue edema, toxic epidermal necrolysis, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to venlafaxine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing the MAO inhibitor); initiation of MAO inhibitor intended to treat psychiatric disorders within 7 days of discontinuing venlafaxine; initiation of venlafaxine in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants in children and teenagers should be dispensed with each prescription.",
"     <b>",
"      Venlafaxine is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anxiety/insomnia: May cause increase in anxiety, nervousness, and insomnia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin or NSAIDs due to ulcerogenic potential. Data are inconclusive regarding extent of bleeding risk of SNRIs in combination with warfarin or other anticoagulants. Bleeding related to SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: May cause significant increases in serum total cholesterol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Dose-related increases in systolic and diastolic blood pressure have been documented. Monitor blood pressure regularly, and if sustained increases noted, consider dose reduction or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary events: Interstitial lung disease and eosinophilic pneumonia have been rarely reported. May present as progressive dyspnea, cough, and/or chest pain. Prompt evaluation and possible discontinuation of therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea),; and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;text-align:justify;\">",
"     &bull; Weight loss and anorectic effects: Dose-dependent weight loss has been observed in both pediatric and adult patients; weight loss was not limited to those experiencing reduced appetite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: May cause sustained increase in blood pressure or tachycardia. Control pre-existing hypertension prior to initiation of venlafaxine. Use caution in patients with recent history of MI, unstable heart disease, or hyperthyroidism. Hypertensive effect is dose related and increases are generally modest (12-15 mm Hg diastolic).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution; clearance is decreased and plasma concentrations are increased; dosage reduction recommended in patients with mild-to-moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Venlafaxine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narrow-angle glaucoma: May cause mydriasis; use caution in patients with increased intraocular pressure or at risk of acute narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution; clearance is decreased and plasma concentrations are increased; dosage reduction recommended in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use caution with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Concurrent therapy with other drugs which lower the seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Pediatrics: Small differences in height and weight have been observed in pediatric patients receiving venlafaxine, particularly those &lt;12 years of age, compared to placebo. Not FDA approved for use in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: Abrupt discontinuation or dosage reduction has been associated with a wide range of reactions, including (but not limited to) dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, impaired coordination/balance, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of venlafaxine therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Venlafaxine may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Venlafaxine. Specifically, the risk of serotonin syndrome may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Venlafaxine. Management: Monitor for increased venlafaxine levels/adverse effects (e.g., hallucinations, agitation, confusion) with propafenone initiation/dose increase. Conversely, monitor for decreased venlafaxine levels with profapenone discontinuation/dose decrease.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Venlafaxine may enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Venlafaxine may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F233757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava, tryptophan (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Venlafaxine and its active metabolite ODV cross the human placenta. An increased risk of teratogenic effects following venlafaxine exposure during pregnancy has not been observed, based on available data. The risk of spontaneous abortion may be increased. Neonatal seizures and neonatal abstinence syndrome have been noted in case reports following maternal use of venlafaxine during pregnancy. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SNRI or a discontinuation syndrome and may be consistent with serotonin syndrome associated with treatment. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SNRI/SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of venlafaxine may be altered. Women should be monitored for decreased efficacy. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F233746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Venlafaxine and ODV are found in breast milk and the serum of nursing infants. Adverse events have not been observed; however, it is recommended to monitor the infant for adverse events if the decision to breast-feed has been made. The long-term effects on neurobehavior have not been studied, thus one should prescribe venlafaxine to a mother who is breast-feeding only when the benefits outweigh the potential risks. The manufacturer does not recommend breast-feeding during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F233747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F233744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Effexor XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (30): $186.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $208.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $227.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Venlafaxine HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (30): $124.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $139.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $152.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Venlafaxine HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (30): $102.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $114.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $124.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 mg (30): $239.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Venlafaxine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $194.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (100): $200.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $206.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $218.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $231.53",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure should be regularly monitored, especially in patients with a high baseline blood pressure; may cause mean increase in heart rate of 4-9 beats/minute; cholesterol; mental status for depression, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; signs/symptoms of serotonin syndrome;   height and weight should be monitored in children",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ansifix SR (EC);",
"     </li>",
"     <li>",
"      Blossom (CL);",
"     </li>",
"     <li>",
"      Calmdown (TW);",
"     </li>",
"     <li>",
"      Cofexor XL ER (KP);",
"     </li>",
"     <li>",
"      Dobupal (ES);",
"     </li>",
"     <li>",
"      Easyfor SR (TW);",
"     </li>",
"     <li>",
"      Efectin (AT, CZ, HU, PL);",
"     </li>",
"     <li>",
"      Efectin ER (BG);",
"     </li>",
"     <li>",
"      Efexor (AR, BE, BR, CH, CO, CR, DK, DO, EE, FI, GB, GR, GT, HN, IE, IT, LU, NI, NL, NO, PA, PE, PK, SE, SV, TR, ZA);",
"     </li>",
"     <li>",
"      Efexor Depot (FI, NO, SE);",
"     </li>",
"     <li>",
"      Efexor ER (CH);",
"     </li>",
"     <li>",
"      Efexor XL (ID);",
"     </li>",
"     <li>",
"      Efexor XR (AR, AU, BR, CN, CO, CR, EC, EE, GT, HK, HN, IL, KP, MX, MY, NI, NZ, PA, PE, PH, PT, SG, SV, TH, VE);",
"     </li>",
"     <li>",
"      Effexor (FR);",
"     </li>",
"     <li>",
"      Elafax (PY, UY);",
"     </li>",
"     <li>",
"      Elafax XR (PY, UY);",
"     </li>",
"     <li>",
"      Faxine (TW);",
"     </li>",
"     <li>",
"      Levensa SR (KP);",
"     </li>",
"     <li>",
"      Rafax XR (TW);",
"     </li>",
"     <li>",
"      Trevilor (DE);",
"     </li>",
"     <li>",
"      Trewilor (AT);",
"     </li>",
"     <li>",
"      Valosine (TW);",
"     </li>",
"     <li>",
"      Valosine SR (TH);",
"     </li>",
"     <li>",
"      Vandral (ES);",
"     </li>",
"     <li>",
"      Velapax (RU);",
"     </li>",
"     <li>",
"      Velaxin (HK);",
"     </li>",
"     <li>",
"      Venexor (HK);",
"     </li>",
"     <li>",
"      Venexor XR SR (KP);",
"     </li>",
"     <li>",
"      Veniz-XR (IN);",
"     </li>",
"     <li>",
"      Venla (IL);",
"     </li>",
"     <li>",
"      Venlafact SR (KP);",
"     </li>",
"     <li>",
"      Venlalic XL (GB);",
"     </li>",
"     <li>",
"      Venlax (CN);",
"     </li>",
"     <li>",
"      Venlax Retard (CN);",
"     </li>",
"     <li>",
"      Venlift OD-75 (PH);",
"     </li>",
"     <li>",
"      Ventaxin OR (KP);",
"     </li>",
"     <li>",
"      Venxor (HK);",
"     </li>",
"     <li>",
"      Viepax (IL);",
"     </li>",
"     <li>",
"      Viepax XR (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine and ODV have no significant activity for muscarinic cholinergic, H",
"     <sub>",
"      1",
"     </sub>",
"     -histaminergic, or alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors. Venlafaxine and ODV do not possess MAO-inhibitory activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &ge;92%; food has no significant effect on absorption or formation of active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Venlafaxine 7.5 &plusmn; 3.7 L/kg, ODV 5.7 &plusmn; 1.8 L/Kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Venlafaxine 27% &plusmn; 2%, ODV 30% &plusmn; 12%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2D6 to active metabolite, O-desmethylvenlafaxine (ODV); other metabolites include N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Venlafaxine: 5 &plusmn; 2 hours; ODV: 11 &plusmn; 2 hours; prolonged with cirrhosis (venlafaxine: ~30%, ODV: ~60%), renal impairment (venlafaxine: ~50%, ODV: ~40%), and during dialysis (venlafaxine: ~180%, ODV: ~142%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Venlafaxine: 2 hours, ODV: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Venlafaxine: 5.5 hours, ODV: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~87%; 5% of total dose as unchanged drug; 29% of total dose as unconjugated ODV; 26% of total dose as conjugated ODV; 27% of total dose as minor inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmad S, &ldquo;Venlafaxine and Severe Tinnitus,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1995, 51(8):1830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/7762476/pubmed\" id=\"7762476\" target=\"_blank\">",
"        7762476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(11):1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brubacher JF, Lurin MJ, Hirsch S, et al, &ldquo;Serotonin Syndrome From Venlafaxine-Tranylcypromine Interaction,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):523-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Danjou P and Hackett D, &ldquo;Safety and Tolerance Profile of Venlafaxine,&rdquo;",
"      <i>",
"       Int Clin Psychopharmacol",
"      </i>",
"      , 1995, 10(Suppl 2):15-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/7622813/pubmed\" id=\"7622813\" target=\"_blank\">",
"        7622813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Jonghe F and Swinkels JA, &ldquo;The Safety of Antidepressants,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 43(Suppl 2):40-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/1378373/pubmed\" id=\"1378373\" target=\"_blank\">",
"        1378373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellingrod VL and Perry PJ, &ldquo;Venlafaxine: A Heterocyclic Antidepressant,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(24):3033-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/7856622/pubmed\" id=\"7856622\" target=\"_blank\">",
"        7856622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Evans ML, Pritts E, Vittinghoff E, et al, &ldquo;Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):161-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/15625158/pubmed\" id=\"15625158\" target=\"_blank\">",
"        15625158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grothe DR, Scheckner B, and Albano D, &ldquo;Treatment of Pain Syndromes With Venlafaxine,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(5):621-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/15162896/pubmed\" id=\"15162896\" target=\"_blank\">",
"        15162896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodgman M, Martin T, Dean B, et al, &ldquo;Severe Serotonin Syndrome Secondary to Venlafaxine and Maintenance Tranylcypromine Therapy,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):554.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander E, Kaplan A, Cartwright C, et al, &ldquo;Venlafaxine in Children, Adolescents, and Young Adults With Autism Spectrum Disorders: An Open Retrospective Clinical Report,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2000, 15(2):132-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/10695900/pubmed\" id=\"10695900\" target=\"_blank\">",
"        10695900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan A, Fabre LF, and Rudolph R, &ldquo;Venlafaxine in Depressed Outpatients,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1991, 27(2):141-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/1924660/pubmed\" id=\"1924660\" target=\"_blank\">",
"        1924660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamerus KJ, Maloney K, Rudolph RL, et al, &ldquo;Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and Its Active O-desmethyl Metabolite,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1992, 32(8):716-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/1487561/pubmed\" id=\"1487561\" target=\"_blank\">",
"        1487561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ladd CO, Newport DJ, Ragan KA, et al, &ldquo;Venlafaxine in the Treatment of Depressive and Vasomotor Symptoms in Women With Perimenopausal Depression,&rdquo;",
"      <i>",
"       Depress Anxiety",
"      </i>",
"      , 2005, 22(2):94-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/16094663/pubmed\" id=\"16094663\" target=\"_blank\">",
"        16094663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loprinzi CL, Kugler JW, Sloan JA, et al, &ldquo;Venlafaxine in Management of Hot Flashes in Survivors of Breast Cancer: A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9247):2025-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/11145483/pubmed\" id=\"11145483\" target=\"_blank\">",
"        11145483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maidement ID, &ldquo;The Use of Antidepressants to Treat Attention Deficit Hyperactivity Disorder in Adults,&rdquo;",
"      <i>",
"       J Psychopharmacol",
"      </i>",
"      , 2003, 17(3):332-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/14513926/pubmed\" id=\"14513926\" target=\"_blank\">",
"        14513926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandoki MW, Tapia MR, Tapia MA, et al, &ldquo;Venlafaxine in the Treatment of Children and Adolescents With Major Depression,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1997, 33(1):149-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/9133767/pubmed\" id=\"9133767\" target=\"_blank\">",
"        9133767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olvera RL, Pliszka SR, Luh J, et al, &ldquo;An Open Trial of Venlafaxine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1996, 6(4):241-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/9231317/pubmed\" id=\"9231317\" target=\"_blank\">",
"        9231317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phelps NJ and Cates ME, &ldquo;The Role of Venlafaxine in the Treatment of Obsessive-Compulsive Disorder,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(1):136-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/15585743/pubmed\" id=\"15585743\" target=\"_blank\">",
"        15585743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sena SF, Kazimi S, and Wu AH, &ldquo;False-Positive Phencyclidine Immunoassay Results Caused by Venlafaxine and O-desmethylvenlafaxine,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 2002; 48(4):676-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/11901076/pubmed\" id=\"11901076\" target=\"_blank\">",
"        11901076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/18628446/pubmed\" id=\"18628446\" target=\"_blank\">",
"        18628446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tzallas PJ and Rynn KO, &ldquo;Extrapyramidal Side Effects Secondary to Venlafaxine,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):518.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Venlafaxine: A New Dimension in Antidepressant Pharmacotherapy,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1993, 54(3):119-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/8468312/pubmed\" id=\"8468312\" target=\"_blank\">",
"        8468312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weller EB, Weller RA, and Davis HP, &ldquo;Use of Venlafaxine in Children and Adolescents: A Review of Current Literature,&rdquo;",
"      <i>",
"       Depress Anxiety",
"      </i>",
"      , 2000, 12(Suppl 1):85-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/11098420/pubmed\" id=\"11098420\" target=\"_blank\">",
"        11098420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zajecka JM, Fawcett J, and Guy C, &ldquo;Coexisting Major Depression and Obsessive-Compulsive Disorder Treated With Venlafaxine,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1990, 10(2):152-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/45/22233/abstract-text/2341595/pubmed\" id=\"2341595\" target=\"_blank\">",
"        2341595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10042 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22233=[""].join("\n");
var outline_f21_45_22233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5710003\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233802\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2237702\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233769\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233770\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233734\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233719\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874929\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233739\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233738\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233798\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914389\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233800\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233742\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233723\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233795\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233728\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233757\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233729\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233745\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233774\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233746\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233747\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233744\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233731\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233748\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233722\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233741\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=related_link\">",
"      Venlafaxine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/18/19752?source=related_link\">",
"      Venlafaxine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_45_22234="Chronic beryllium disease (berylliosis)";
var content_f21_45_22234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic beryllium disease (berylliosis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Lee S Newman, MD, MA, FCCP, FACOEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Lisa A Maier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/45/22234/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/45/22234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic beryllium disease (CBD), also called berylliosis, is a granulomatous disease caused by exposure to beryllium. Beryllium is an alkaline earth metal that is used in a number of different industrial applications. CBD shares many clinical and histopathological features with sarcoidosis and was first described in 1946 when 17 fluorescent lamp workers presented with a syndrome of advanced pulmonary granulomatous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, sources of exposure, clinical and laboratory findings, diagnosis, and treatment of CBD will be reviewed here. The evaluation of the adult with interstitial lung disease and the clinical manifestations and diagnosis of sarcoidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient is considered to have chronic beryllium disease (CBD) if",
"    <strong>",
"     all",
"    </strong>",
"    of the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of any beryllium exposure",
"     </li>",
"     <li>",
"      A positive blood or bronchoalveolar lavage (BAL) beryllium lymphocyte proliferation test (BeLPT) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Beryllium lymphocyte proliferation test'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Noncaseating granulomas on lung biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A patient is considered to have beryllium sensitization when they have a positive BeLPT performed on blood or BAL mononuclear cells, but no lung pathology. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Beryllium lymphocyte proliferation test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beryllium, which is lighter than aluminum and six times stronger than steel, is often alloyed with copper, aluminum, and nickel [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Exposure to beryllium may occur among workers in the following industries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heavy beryllium-using industries: metal and metal alloy (beryllium-copper) machine shops, electronics, defense industry, and beryllium extraction",
"     </li>",
"     <li>",
"      Other beryllium-using industries: automotive, ceramic, computer, aerospace, metal reclamation, electronics and computer recycling, jewelry making, and dental",
"      <span class=\"nowrap\">",
"       alloy/appliance",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact exposure-response relationship for CBD is unclear. Both the dose and duration of beryllium exposure appear to be associated with an increased risk of sensitization and disease, with rates as high as 20 percent in certain higher exposure work tasks (eg, beryllium ceramics, machining, rod and wire production) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/7,9-13\">",
"     7,9-13",
"    </a>",
"    ]. However, the relationship does not appear to be linear, and the overall rate of CBD appears to be between 1 and 5 percent, according to cross-sectional studies of beryllium-using workplaces [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/7-20\">",
"     7-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current US Occupational Safety and Health Administration (OSHA) industrial exposure limit for airborne beryllium (2",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    time weighted average exposure for an eight hour day) is not completely protective against CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/6,8-11,13,16-18,20\">",
"     6,8-11,13,16-18,20",
"    </a>",
"    ]. Some individuals develop clinically significant illness even at extremely low levels of exposure or after an exposure as short as three months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/14\">",
"     14",
"    </a>",
"    ]. Examples include those working in decontamination and decommission of old buildings in which beryllium had been used, construction trade workers, security guards, and secretaries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/7,8,15,19,21-23\">",
"     7,8,15,19,21-23",
"    </a>",
"    ]. It is estimated that between 134,000 and 800,000 current and former workers have been exposed to beryllium in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The problem is not confined to the United States; cases of CBD have also been reported elsewhere in North America, South America, Europe, and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community acquired chronic beryllium disease has also been described in a small number of residents living within five miles of beryllium manufacturing facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/26\">",
"     26",
"    </a>",
"    ]. In a community survey of residents without occupational exposure to beryllium, disease manifestations sometimes developed 19 to 52 years after community-based exposure had ceased and were associated with substantial morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of chronic beryllium disease appears to involve a combination of an immunologic response to beryllium exposure and an underlying genetic susceptibility, although the reasons for persistence and progression of lung disease following cessation of exposure are less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunologic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CBD and in beryllium-sensitized patients, beryllium elicits an immunologic reaction with characteristics of a cell-mediated or delayed hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link&amp;anchor=H1231136#H1231136\">",
"     \"Normal B and T lymphocyte development\", section on 'T cell development'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link&amp;anchor=H14#H14\">",
"     \"T helper subsets: Differentiation and role in disease\", section on 'T helper subsets in disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .) These characteristics include beryllium-specific sensitization of T cells, proliferation of T cells upon re-exposure, production and release of proinflammatory cytokines, and granulomatous inflammation. As the lungs are the typical portal of entry of beryllium, it is not surprising that the immune response is most strongly evident in the lungs.",
"   </p>",
"   <p>",
"    Studies of peripheral blood lymphocytes isolated from patients with CBD have shown that reexposure to beryllium in vitro typically induces a proliferative response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/30\">",
"     30",
"    </a>",
"    ]. This proliferative response is specific for beryllium and is not induced by other metals. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Beryllium lymphocyte proliferation test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, studies of mononuclear cells obtained by bronchoalveolar lavage (BAL) from patients with CBD support the immunologic role of beryllium in the pathogenesis of CBD. The BAL cells were found to be relatively rich in CD4+ T cells that proliferated when cultured in vitro with beryllium salts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/31\">",
"     31",
"    </a>",
"    ]. This T cell proliferative response could be abrogated with antibodies directed to MHC II, but not MHC I [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Genetic susceptibility'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Constituents of BAL in ILD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experimental studies have also demonstrated that beryllium, when bound to proteins such as ferritin, can be taken up by antigen presenting cells and elicit a response from sensitized lymphocytes at concentrations five to six logs lower than the concentration of beryllium sulfate (BeSO",
"    <sup>",
"     4",
"    </sup>",
"    ) typically required to induce proliferation. The enhanced antigenic potency of beryllium protein complexes provides a potential mechanism to explain how extremely low environmental levels of beryllium exposure in the workplace can induce sensitization and disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung mononuclear cell inflammation and granuloma formation are presumably maintained by the accumulation in the lung of large numbers of CD4+ memory T cells specific for either beryllium itself, beryllium associated with HLA-DP or HLA-DR, or beryllium bound to an exogenous or endogenous peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/33\">",
"     33",
"    </a>",
"    ]. Beryllium sensitization is predominantly a Th1 response involving interferon gamma and interleukin-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, cells collected by BAL from patients with CBD express increased levels of tumor necrosis factor-alpha and interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/35\">",
"     35",
"    </a>",
"    ]. These cytokines (in conjunction with T cell cytokines) are thought to be important in the initiation and maintenance of the human granulomatous response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several hypotheses have been developed to explain why CBD persists and progresses after removal from exposure to beryllium. One possibility is that the metal antigen is retained in the lung due to the solubility of beryllium and its ability to cause macrophages to undergo apoptosis and re-release previously phagocytosed beryllium particles [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Another potential explanation for the persistence of the immune response comes from the identification of a deficient and dysfunctional population of regulatory T (Treg) cells in the BAL fluid obtained from patients with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39\">",
"     39",
"    </a>",
"    ]. The impaired functional capacity of the Treg cells may decrease the suppression of CD4+ T cell proliferation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link&amp;anchor=H11#H11\">",
"     \"T helper subsets: Differentiation and role in disease\", section on 'Modulation by regulatory T cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H25#H25\">",
"     \"The adaptive cellular immune response\", section on 'Suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA disease associations and susceptibility to abnormal immune reactions are believed to reflect single amino acid changes in the HLA molecule hypervariable regions critical to antigen presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/40\">",
"     40",
"    </a>",
"    ]. In this regard, the HLA-DP&szlig;1 gene comprises six hypervariable coding regions. Eighty-five percent of patients with CBD (compared to 40 to 45 percent of controls) have an HLA-DP&szlig;1 variant, which contains a glutamate for lysine substitution at position 69 at one of the hypervariable regions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/21,41-46\">",
"     21,41-46",
"    </a>",
"    ]. More recently, HLA- DR&szlig;1 variants with similar negatively charged amino acids (glutamate at position 71) in the antigen binding pocket have been shown to be associated with CBD risk, particularly in those individuals who do not have the HLA-DP DP&szlig;1 glutamate 69 variant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link&amp;anchor=H5#H5\">",
"     \"Human leukocyte antigens (HLA): A roadmap\", section on 'Class II region'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, these genotypes are markers for susceptibility to beryllium sensitivity and CBD among exposed individuals. However, they are not appropriate screening tools given the relatively high prevalence of these genotypes in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/41,42,44,47,48\">",
"     41,42,44,47,48",
"    </a>",
"    ]. Similarly, TNF-alpha polymorphisms have been associated with beryllium-induced expression of TNF-alpha mRNA and protein by CBD patients' blood and bronchoalveolar lavage cells, but not with CBD or risk of beryllium sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Additional genetic factors are likely involved in the risk of beryllium sensitization, progression to CBD, and more severe disease, although these are unclear at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of CBD are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/52\">",
"     52",
"    </a>",
"    ]. Common symptoms include dry cough, shortness of breath, fever, night sweats, fatigue, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/8,39\">",
"     8,39",
"    </a>",
"    ]. Bronchial involvement can produce symptoms similar to those of asthma. The latency period between initial beryllium exposure and onset of symptoms varies from three months to 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous nodules can develop, especially if beryllium has penetrated the skin (",
"    <a class=\"graphic graphic_picture graphicRef81104 \" href=\"UTD.htm?29/11/29872\">",
"     picture 1",
"    </a>",
"    ). These nodules tend to be located on exposed areas of skin, such as fingers and forearms and are generally smaller than the cutaneous nodules seen in sarcoidosis. Pulmonary examination typically reveals bibasilar crackles; more advanced disease may be associated with signs of cor pulmonale and digital clubbing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621415692\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with suspected CBD includes identifying beryllium sensitization of peripheral blood and bronchoalveolar cells with beryllium lymphocyte proliferation testing, assessing the severity of disease with pulmonary function testing, determining whether the pattern seen on chest imaging is compatible with CBD, and confirming the diagnosis with histopathologic analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271805197\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of routine laboratory tests are typically nonspecific. Measurement of the serum angiotensin converting enzyme (ACE) level is not helpful, as it does not discriminate between patients with CBD, beryllium sensitization, beryllium exposure, or sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/53\">",
"     53",
"    </a>",
"    ]. Among 23 patients with CBD, only 22 percent had an elevated serum ACE level [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Serum ACE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    may be performed in patients being evaluated for CBD to exclude TB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Tuberculin skin test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A blood beryllium lymphocyte proliferation test (BeLPT) is the most appropriate initial test for patients suspected of having CBD. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Beryllium lymphocyte proliferation test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As in other granulomatous diseases of the lung, increased production of calcitriol (the most active form of vitamin D) by activated pulmonary macrophages can lead to hypercalciuria and hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending on the strength of the history of beryllium exposure, laboratory testing for other types of interstitial lung disease (eg, connective tissue disease, eosinophilic lung diseases, vasculitis) should follow the usual guidelines (",
"    <a class=\"graphic graphic_table graphicRef55597 \" href=\"UTD.htm?26/12/26828\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Laboratory tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H32#H32\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Laboratory abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are obtained an all patients suspected of having CBD. Depending on the time course and severity of disease, the chest radiograph may be normal or may show hilar adenopathy or parenchymal abnormalities such as nodules, ground glass, linear, or alveolar opacities. The parenchymal abnormalities may be diffuse or may be more prominent in the upper lobes.",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) is more sensitive than a plain chest radiograph in identifying the changes of CBD; however, high resolution CT scanning is normal in up to 25 percent of patients with biopsy-proven CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/54\">",
"     54",
"    </a>",
"    ]. The HRCT findings associated with CBD include parenchymal nodules of varying size, thickened septal lines, ground glass opacities, cystic cavitation, bronchial wall thickening, and adenopathy involving the hilum or mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Pleural thickening may be observed adjacent to areas of dense subpleural parenchymal nodules, but pleural effusions are uncommon. Pneumothorax has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests are obtained in virtually all patients suspected of having CBD on the basis of dyspnea, an abnormal chest radiograph, or a history of exposure to beryllium. Early in the course of CBD, the pulmonary function abnormalities, if present at all, include mild airflow limitation and abnormal gas exchange at rest or during exercise (manifested as worsening hypoxemia with increasing exercise). Diffusing lung capacity for carbon monoxide (DLCO) is commonly diminished, although this test is less sensitive than arterial blood gas analysis at rest and exercise. As the disease becomes more clinically apparent, spirometry shows airflow limitation, restriction, or a mixed pattern. Pure restriction is a relatively late finding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271805890\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis OF CBD includes sarcoidosis, other granulomatous lung diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388828#H11388828\">",
"     \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Granulomatous lung diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the strong clinical and histopathological resemblance of sarcoidosis and CBD, patients are sometimes misdiagnosed with sarcoidosis until the history of exposure to beryllium is elicited and beryllium hypersensitivity demonstrated with specific testing. As an example, it is estimated that up to 6 percent of all patients diagnosed with sarcoidosis may actually have CBD, although the exact proportion depends on the clinic&rsquo;s referral population and the degree of clinical suspicion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/2,3,59\">",
"     2,3,59",
"    </a>",
"    ]. Among patients diagnosed with sarcoidosis in whom beryllium exposure can be confirmed, as many as 40 percent may actually have CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Beryllium lymphocyte proliferation test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CBD requires that all three of the following findings be present: a history of beryllium exposure, a positive beryllium lymphocyte proliferation test (BeLPT), and the presence of noncaseating granulomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mononuclear cell interstitial cell infiltrates on lung biopsy. When histopathology is unavailable, the diagnosis can be made based on the history of exposure, a positive BeLPT, and imaging that shows abnormalities consistent with CBD. As a general approach to diagnosis, all patients with clinical or radiographic evidence of lung disease or an occupational or environmental history of beryllium exposure should be evaluated for CBD. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Beryllium lymphocyte proliferation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood beryllium lymphocyte proliferation test (BeLPT) is the most appropriate initial test for patients suspected of having CBD and has become the standard industry surveillance tool for identifying beryllium-exposed workers who are beryllium-sensitized or in the early stages of CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/31,60,61\">",
"     31,60,61",
"    </a>",
"    ]. The BeLPT is also used to correct misdiagnoses of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the BeLPT assay, mononuclear cells from peripheral blood or bronchoalveolar lavage (BAL) are exposed in vitro to three different concentrations of beryllium salts (eg, beryllium sulfate) for two different time intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/62\">",
"     62",
"    </a>",
"    ]. Cell proliferation is measured by the incorporation of tritiated thymidine into the DNA of dividing cells. The cutoff value for a positive test is laboratory-dependent. If none of the six resultant tests show increased lymphocyte proliferation, the test is normal. If one of the six incubations shows increased uptake, the test is borderline. If two or more of the incubations show increased uptake the test is abnormal. The specificity of in vitro generated beryllium-reactive cells can be demonstrated by the lack of response to other metals and by the normal stimulation index of those exposed to beryllium without evidence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/31,63,64\">",
"     31,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of a single peripheral blood BeLPT is 0.683 and the specificity 0.96 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/65\">",
"     65",
"    </a>",
"    ]. To improve the sensitivity of the testing and to resolve borderline test results, all negative and borderline tests are generally repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. If the second test is either positive or borderline, the patient is considered to be sensitized to beryllium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/62\">",
"     62",
"    </a>",
"    ]. Among patients with a positive blood BeLPT, 20 to 100 percent will have evidence of CBD based on bronchoalveolar lavage (BAL) or transbronchial biopsy results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/6,11,13,14,66\">",
"     6,11,13,14,66",
"    </a>",
"    ]. This wide range is likely related to variations in the magnitude of beryllium exposure in the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, if both rounds of BeLPT testing are negative, the patient may still have CBD, as the false negative rate of BeLPT testing on peripheral blood remains approximately 30 percent even after two rounds of testing. Thus, for an individual with clinical evidence of lung disease and a history of exposure to beryllium, even at very low levels, further testing for CBD (eg, bronchoalveolar lavage, tissue biopsy) would be indicated even if the blood BeLPT is negative. &nbsp;",
"   </p>",
"   <p>",
"    If BeLPT testing is not available locally, blood and BAL samples are sent to a reference laboratory (eg, National Jewish Health,",
"    <a class=\"external\" href=\"file://www.nationaljewish.org/research/diagnostics/adx/requisitions/bal-belpt.aspx\">",
"     file://www.nationaljewish.org/research/diagnostics/adx/requisitions/bal-belpt.aspx",
"    </a>",
"    ) or ORISE Beryllium Testing Laboratory",
"    <a class=\"external\" href=\"file://orise.orau.gov/worker-health-studies/capabilities/beryllium-exposure-studies-testing/beryllium-testing-laboratory.aspx\">",
"     file://orise.orau.gov/worker-health-studies/capabilities/beryllium-exposure-studies-testing/beryllium-testing-laboratory.aspx",
"    </a>",
"   </p>",
"   <p>",
"    Experimental variations on the BeLPT have been developed in an effort to improve detection of lymphocyte proliferation. These tests use flow cytometry to assess lymphocytes that have entered cell cycle upon stimulation with beryllium salts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/32,68,69\">",
"     32,68,69",
"    </a>",
"    ]. A separate investigational approach monitors in vitro macrophage production of neopterin following beryllium stimulation, as an indicator of beryllium-induced TNF-alpha and gamma interferon activation. Although this modification of the blood BeLPT may eventually help differentiate beryllium sensitization from CBD, it requires further investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another experimental approach to distinguishing between beryllium sensitization and CBD without invasive procedures, called a beryllium ELISPOT test, assesses the number of beryllium-specific CD4+ T cells in the peripheral blood. Patients with CBD tend to have higher numbers of these circulating beryllium-specific T cells than subjects with sensitization alone; however, the accuracy and predictive value of beryllium ELISPOT test remain under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6629538\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have a positive peripheral blood BeLPT or a clear history of exposure to beryllium, we perform bronchoscopy with a bronchoalveolar lavage (BAL) to obtain cell counts and a sample of BAL mononuclear cells for BeLPT testing. A portion of the BAL fluid is also sent for cytology and cultures (eg, actinomycosis, nocardia, mycobacterial, fungal). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link&amp;anchor=H7#H7\">",
"     \"Basic principles and technique of bronchoalveolar lavage\", section on 'Processing the lavage specimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The technique for obtaining BAL fluid for BeLPT testing differs from the usual BAL technique due to the requirement for a large number of cells. The exact specifications for preparation and transportation of the BAL cells for BeLPT may vary between laboratories and should be confirmed with the laboratory prior to performing the BAL. During bronchoscopy, we perform the BAL prior to any biopsy procedures to avoid contamination of the fluid with blood from a biopsy. After wedging the bronchoscope in an area of lung believed to have active disease based on the HRCT, we typically do four successive 60 mL saline lavages to a total instilled volume of 240 mL. If the lung is diffusely involved, we perform the BAL in either the lingula or right middle lobe. If the return from the lavage is less than 50 percent, an additional lavage may be performed in a separate site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link&amp;anchor=H3#H3\">",
"     \"Basic principles and technique of bronchoalveolar lavage\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After samples for other studies have been set aside, the BAL fluid is centrifuged at approximately 1200 RPM for 10 minutes. The supernatant is discarded and the cells are resuspended in a plastic centrifuge tube with a mixture of RPMI 1640 (or similar tissue culture medium),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    sulfate or",
"    <span class=\"nowrap\">",
"     penicillin/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"      streptomycin",
"     </a>",
"    </span>",
"    (0.5 percent by volume), and pooled AB positive serum or the patient&rsquo;s own serum at 10 percent by volume. The final concentration of cells in the media should be approximately 5 to 10 million cells per mL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/74\">",
"     74",
"    </a>",
"    ]. The sample is kept at room temperature and transported immediately to the laboratory performing the BeLPT test, which must be notified prior to obtaining and sending the specimen.",
"   </p>",
"   <p>",
"    Approximately 10 to 35 percent of patients with beryllium sensitivity have a negative BeLPT test on peripheral blood, but a positive test on BAL mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/65\">",
"     65",
"    </a>",
"    ]. One explanation for this observation is that cells obtained from BAL generally yield higher peak stimulation responses to beryllium salts than cells from peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/75\">",
"     75",
"    </a>",
"    ]. However, occasionally BAL proliferation assays give false negative results due to a significant excess of alveolar macrophages in the lavage, which is a common finding among cigarette smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Processing BAL fluid for BeLPT is more complicated than processing peripheral blood, and is not available in most medical centers. If testing is not available locally, blood and BAL fluid can be sent by overnight courier to one of the centers that perform this specialized assay on a regular basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial and transbronchial biopsies are usually obtained at the time of flexible fiberoptic bronchoscopy to fulfill the third criterion for CBD diagnosis. Endobronchial biopsies are useful because noncaseating granulomas have been identified in the bronchial wall in approximately thirty percent of patients with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/76\">",
"     76",
"    </a>",
"    ]. Four to six endobronchial biopsies are typically obtained from a site where the mucosa appears erythematous; if the mucosa appears normal throughout, endobronchial biopsies are obtained from the main carina and a secondary carina [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H22747937#H22747937\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Endobronchial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transbronchial biopsies are typically obtained from an area of involved lung (identified by the HRCT scan appearance), but not the same site as a BAL performed during the same procedure. We typically obtain eight to ten transbronchial biopsy pieces (as tolerated by the patient) to maximize the yield [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Transbronchial lung biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H5040289#H5040289\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Transbronchial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When preparing samples from transbronchial lung biopsies for histopathologic analysis, at least 10 sections should be made from the tissue block in order to reduce the chance of missing granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/78\">",
"     78",
"    </a>",
"    ]. The typical pathologic findings of CBD are noncaseating granulomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mononuclear cell infiltrates in the bronchial wall or lung interstitium. In some patients, the same pathology can be detected in the regional lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/76,79\">",
"     76,79",
"    </a>",
"    ]. Biopsies of beryllium-induced skin nodules also typically demonstrate noncaseating granulomas. While it is possible to measure beryllium inside granulomas using mineral analytic methods that can demonstrate increased levels of beryllium within granulomas, this testing is not commonly used to diagnose CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with clinical evidence of CBD based on exposure history and pulmonary function testing or high resolution computed tomography, approximately 5 to 10 percent have false-negative biopsies and require either repeat bronchoscopy or video-assisted thoracoscopic lung biopsy. False negative results should be suspected if the lavage lymphocyte percentage is elevated (eg, &gt;20 percent in nonsmokers) and the beryllium lymphocyte proliferation test (BeLPT) is positive on either the blood or bronchoalveolar lavage (BAL) samples [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the BeLPT on BAL lymphocytes is positive, but transbronchial biopsies are inadequate or cannot be obtained, BAL lymphocytosis may be used as a surrogate marker for underlying pathology. BAL lymphocytosis is usually defined as greater than 30 percent lymphocytes (the 95 percentile for never smokers) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/80\">",
"     80",
"    </a>",
"    ]. However, BAL lymphocytosis is not specific for CBD, unless the BeLPT is performed using the BAL cells. For patients with BAL lymphocytosis and a negative BAL BeLPT, further evaluation for other causes of BAL lymphocytosis is needed (",
"    <a class=\"graphic graphic_table graphicRef69908 \" href=\"UTD.htm?3/47/3835\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Role of bronchoalveolar lavage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H3#H3\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Lymphocytic BAL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CBD includes avoidance of further exposure, supportive care, and therapy with glucocorticoids or other immunosuppressive agents, depending on the severity of symptoms, physiologic impairment, and radiographic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6629594\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with CBD should be removed from further exposure to beryllium to the extent possible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. It is less clear whether patients with beryllium sensitization but no evidence of CBD need to be removed from exposure, but we believe that this is prudent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/76,81\">",
"     76,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not specifically studied in patients with CBD, supportive therapies, including influenza and pneumococcal vaccination and smoking cessation counselling, are provided to all patients; supplemental oxygen and pulmonary rehabilitation are prescribed as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link&amp;anchor=H4#H4\">",
"     \"Long-term supplemental oxygen therapy\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H775052687#H775052687\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286381505\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271806695\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate active treatment for CBD is based on the severity of symptoms and physiologic impairment, evidence of progression, and presence of co-morbid disease that would affect the risk of systemic glucocorticoid therapy. Treatment is usually initiated when the patient reports bothersome dyspnea or cough; when there has been a greater than 10 percent decline in lung volumes or gas exchange compared to baseline; or when the patient has abnormal physiology at baseline (eg, lung volumes or DLCO less than 70 percent of predicted) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/81\">",
"     81",
"    </a>",
"    ]. The decision to treat with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    requires balancing the medication's potential benefits against the patient's risk for side effects such as diabetes mellitus, hypertension, osteoporosis, and increased susceptibility to infection.",
"   </p>",
"   <p>",
"    Patients with beryllium sensitization in the absence of CBD do not require treatment, but should undergo annual or biennial evaluation for progression into CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients who have documented CBD, but minimal or absent symptoms and physiologic abnormalities, also do not require active treatment, but are reassessed at six to twelve month intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271806688\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of systemic glucocorticoid therapy for CBD has not been evaluated in controlled clinical trials. However, the response to glucocorticoid therapy has been documented in case reports and case series for more than 40 years, making it the standard treatment for CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39,52,81,83\">",
"     39,52,81,83",
"    </a>",
"    ]. As an example, in a series of eight patients with CBD and nodules, micronodules with hazy borders, or ground glass opacities on HRCT, all patients experienced symptomatic and radiographic improvement with glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39\">",
"     39",
"    </a>",
"    ]. By 12 months, lung volumes had improved in all patients; diffusing capacity had improved in seven; and the arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) had improved in seven. In two patients who had initial improvement with glucocorticoid therapy, subsequent deterioration in lung function occurred, accompanied by progression of fibrosis on the HRCT. In a separate series, seven symptomatic patients were treated with systemic glucocorticoids; two improved, four had stable, but persistent disease, and one died [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of glucocorticoid therapy may be improved by initiating therapy before fibrotic disease becomes established. As an example, in a small series, the patients who responded to glucocorticoid therapy had a time interval from onset of symptoms to initiation of therapy of 1.1 years and those who did not respond had an interval of 9.9 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286381525\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for CBD, the usual initial dose is 0.5 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (approximately 40 mg) per day [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39,82\">",
"     39,82",
"    </a>",
"    ]. Approximately 6 to 12 weeks after initiating prednisone, the patient&rsquo;s symptoms, spirometry, lung volumes, and gas exchange (eg, diffusing capacity [DLCO], arterial blood gases, pulse oxygen saturation at rest and on exertion) are reassessed. Once a clinical response is noted, the dose of prednisone is tapered to 20 mg daily, or 40 mg on alternate days. Chest imaging may or may not demonstrate improvement.",
"   </p>",
"   <p>",
"    Evaluations are repeated at approximately three month intervals, and the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is gradually tapered to the lowest level needed to maintain physiologic and symptomatic improvement and disease stability, usually about 5 to 10 mg daily. Complete withdrawal of prednisone can result in disease recrudescence, so lifelong therapy is usually continued at the lowest dose of prednisone that controls disease manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/81,84\">",
"     81,84",
"    </a>",
"    ]. In one series, eight patients were treated with glucocorticoids for a median of 69 months (range 20 to 180). Seven of these 8 patients experienced a clinical relapse as the treatment was tapered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39\">",
"     39",
"    </a>",
"    ]. Interestingly, the three patients with Glu69 homozygosity (HLA-DPB1 genes coding for glutamate at position &beta;69) experienced multiple relapses (11 of the 18 total relapses seen in the cohort). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Genetic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621415872\">",
"    <span class=\"h3\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the overall favorable impression of glucocorticoid therapy for CBD, not all patients respond [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39,82\">",
"     39,82",
"    </a>",
"    ]. In some cases failure to respond was attributed to ongoing exposure to beryllium, in others to delayed removal from exposure and delayed initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/82\">",
"     82",
"    </a>",
"    ]. If no improvement in symptoms or physiologic parameters has occurred after six months, a decision is made whether to discontinue glucocorticoid therapy or add another immunosuppressive agent. If there has been a lag time of several years between the onset of symptoms and initiation of therapy or if the chest radiograph and HRCT suggest a greater proportion of fibrotic change, the patient likely does not have reversible disease and glucocorticoid therapy can be tapered and stopped. If the clinical impression supports a greater likelihood of reversible disease, an additional immunosuppressive agent is usually added. (See",
"    <a class=\"local\" href=\"#H271806681\">",
"     'Other immunosuppressive agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286381590\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term therapy with systemic glucocorticoids is associated with a number of potential side effects, including osteoporosis, increased susceptibility to infection, weight gain, cataract formation, and adrenal suppression. To prevent loss of bone mineral density, patients taking systemic glucocorticoids should maintain a calcium intake of 1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and a vitamin D intake of 800",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    through either diet or supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/85\">",
"     85",
"    </a>",
"    ]. The role of additional agents for osteoporosis prevention and the appropriate monitoring and prevention of the many other potential side effects of glucocorticoid treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Toxicity of systemic glucocorticoids by organ system or symptom complex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271806681\">",
"    <span class=\"h2\">",
"     Other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who fail to respond to glucocorticoids or who experience severe side effects, addition of alternative immunosuppressive agents may be tried, although clinical trials supporting their use have not been published. Based on the experience with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy for sarcoidosis, this agent is often chosen for refractory CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/78\">",
"     78",
"    </a>",
"    ]. Prior to initiating methotrexate, liver function tests and hepatitis B and C viral antibody testing are obtained. Patients with evidence of underlying liver disease or chronic infection with hepatitis B or C are not candidates for methotrexate. In addition, ingestion of alcoholic beverages while using low-dose methotrexate is strongly discouraged, and patients who are unwilling to reduce their alcohol consumption to an occasional and minimal level are not treated with methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is usually initiated at a starting dose of 7.5 mg weekly and gradually increased (eg, by 2.5 mg increments every two weeks) until a dose of 10 to 15 mg per week is achieved.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    1 mg daily is routinely given to patients taking chronic low-dose methotrexate therapy. Methotrexate toxicity includes liver inflammation and fibrosis, bone marrow suppression, alopecia, skin rash, gonadal suppression, and teratogenicity. Complete blood counts and liver tests (eg, aminotransferases and albumin) are repeated at 4 to 8 week intervals while escalating the dose and then at 8 to 12 week intervals. After a stable dose is achieved (usually by 6 months of therapy), most clinicians obtain liver tests every 12 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is another potential adjunctive therapy to glucocorticoids, given some success with this agent in patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/81,86\">",
"     81,86",
"    </a>",
"    ]. However, no published data is available to support this choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\", section on 'Azathioprine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the current understanding of immunopathogenesis of CBD, tumor necrosis factor (TNF)-alpha antagonists appear promising as therapeutic agents; however, definitive clinical trial evidence supporting the use of these agents is not available and results in sarcoidosis have been mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link&amp;anchor=H26465141#H26465141\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\", section on 'Tumor necrosis factor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271806535\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBD has a variable clinical course. Among 348 untreated patients with CBD, 28 percent died, although the number of years between disease onset and death was not recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/87\">",
"     87",
"    </a>",
"    ]. Other published mortality rates range from 6 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/23,81,87\">",
"     23,81,87",
"    </a>",
"    ]. The variability appears to depend on the industrial setting, the duration of beryllium exposure after development of CBD, individual variation, and the duration of clinical follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, beryllium extraction workers appear to have a lower mortality rate than those working with beryllium alloys or ceramics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/87\">",
"     87",
"    </a>",
"    ]. The reason for this observation is not known.",
"   </p>",
"   <p>",
"    Among patients with beryllium sensitization without CBD (ie, a positive blood BeLPT, but no lung pathology), the risk of progressing to CBD is clearly increased, compared with non-sensitized workers. The magnitude of risk was evaluated in a longitudinal study of 55 sensitized individuals, 17 of whom (31 percent) developed CBD within a median follow-up of 3.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/76\">",
"     76",
"    </a>",
"    ]. In a separate surveillance study, progression from beryllium sensitization to CBD occurred in 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the disease will be mild or fulminant is not predicted by the duration of exposure or the degree of positivity of the peripheral blood beryllium lymphocyte proliferation test (BeLPT). However, the type or intensity of exposure may influence progression as suggested by a surveillance study that found a higher rate of disease progression among machinists than non-machinists based on pulmonary function and gas exchange testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition, a higher percentage of lymphocytes in the BAL correlates with a greater severity of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/89\">",
"     89",
"    </a>",
"    ]. Tobacco use does not seem to predict a worsened clinical course, and in some studies smokers with beryllium sensitization of peripheral blood lymphocytes were less likely to have CBD at the time of bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/8,76\">",
"     8,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with CBD who receive treatment with glucocorticoids, stabilization or improvement in symptoms and pulmonary function is likely, as long as glucocorticoid therapy is maintained. However, some patients experience progressive deterioration in lung function and development of pulmonary fibrosis, despite cessation of beryllium exposure and maintenance glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/39,82\">",
"     39,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beryllium has been suspected of increasing the risk of lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/90\">",
"     90",
"    </a>",
"    ]; however, studies with careful adjustment for the risk attributable to cigarette smoking have not supported a significant increase in risk due to beryllium exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/91-94\">",
"     91-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271806542\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The permissible limit for occupational exposure to beryllium that was designed to prevent CBD was 2",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    as an eight hour time weighted average. However, beryllium sensitization has been identified in approximately 10 percent of workers with lower exposures, leading to calls for lower permissible exposure limits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/6,95\">",
"     6,95",
"    </a>",
"    ]. As an example, among five workers at a precious metal refinery who developed CBD, four had carefully documented exposure levels that were less than 2",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of workers in a beryllium machining facility, workers who developed beryllium hypersensitivity or CBD were exposed to beryllium concentrations in the ambient air above 0.2",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (95th percentile) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/95\">",
"     95",
"    </a>",
"    ]. Among workers at the facility who developed CBD, 90 percent were exposed to concentrations greater than 0.4",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    within a given year of their work history. Based on this analysis, it was suggested that maintaining exposure levels below 0.2",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    for 95 percent of the time might prevent beryllium sensitization and CBD. Further work is needed to determine a level of exposure to beryllium that is safe for all workers, including those with a genetic predisposition to sensitization.",
"   </p>",
"   <p>",
"    In the meantime, there are a number of ways to minimize occupational exposure to beryllium. These include having companies use safer metals, improving ventilation systems to reduce dust, administrative controls such as minimizing the number of workers allowed into beryllium areas, providing personal protective equipment (eg, respirators) when exposures cannot be adequately controlled, and educating workers in how to reduce the risk of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/17\">",
"     17",
"    </a>",
"    ]. Dermal exposure can also contribute to risk of beryllium sensitization; therefore, measures should be taken to protect skin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/45/22234/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271806246\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic beryllium disease (CBD), also called berylliosis, is caused by exposure to respirable beryllium metal or alloys and is characterized by the presence of noncaseating granulomas in the lungs. CBD shares many clinical and histopathological features with pulmonary sarcoidosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beryllium exposure occurs in various industries, including beryllium and beryllium alloy (beryllium-copper) machining, the aerospace, automotive, ceramics, computer, defense, and electronic industries. Community acquired chronic beryllium disease has also been described. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CBD requires all three of the following findings: a history of beryllium exposure, a positive beryllium lymphocyte proliferation test (BeLPT), and the presence of noncaseating granulomas",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mononuclear cell interstitial cell infiltrates on lung biopsy. However, if biopsies are not available or are nondiagnostic, the diagnosis can be made based on the history of exposure, a positive BeLPT, and imaging that shows abnormalities consistent with CBD. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with a history of beryllium exposure, the diagnosis of CBD should be suspected in the presence of dyspnea, cough, or a chest radiograph showing show hilar adenopathy or reticular and nodular lung opacities. A high resolution computed tomographic (HRCT) scan is usually obtained to characterize the radiographic pattern and to identify the areas of greatest involvement for bronchoalveolar lavage or potential biopsy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Chest imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of berylliosis includes sarcoidosis, other granulomatous lung diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and asthma. (See",
"      <a class=\"local\" href=\"#H271805890\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A blood beryllium lymphocyte proliferation test (BeLPT) is the initial diagnostic test of choice for patients with clinical or radiographic evidence of lung disease and an occupational or environmental history of beryllium exposure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Beryllium lymphocyte proliferation test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a positive blood BeLPT or a strong clinical suspicion for CBD despite a negative blood BeLPT, the next test is usually fiberoptic bronchoscopy with bronchoalveolar lavage (BAL), endobronchial biopsy, and transbronchial biopsy. To obtain an adequate number of cells for BeLPT, a BAL volume of approximately 240 mL of saline (in 4 aliquots) is used. BAL fluid is also sent for cell and differential counts and also microbiologic and cytologic analyses. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Beryllium lymphocyte proliferation test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who meet criteria for beryllium sensitization, but not CBD, we suggest cessation of exposure to beryllium (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6629594\">",
"       'Supportive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who meet criteria for CBD, we recommend cessation of exposure to beryllium (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For those who have minimal to no symptoms and mild or no impairment in physiologic testing, we recommend against initiating treatment, pending evidence of disease progression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). These patients will require periodic reassessments of symptoms and lung physiologic testing. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bothersome cough or dyspnea, initial values for forced vital capacity, total lung capacity, or diffusing capacity that are below 70 percent of predicted, or a decline of greater than 10 percent during an observation period, we recommend treatment with systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Typically,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is initiated at a dose of 0.5 to 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (approximately 40 mg) per day. Tapering of prednisone is guided by the clinical response. Usually after six to eight weeks, prednisone is tapered to 20 mg daily (or 40 mg on alternate days) and after several months to 5 to 10 mg daily (or 10 to 20 mg on alternate days). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail to respond to glucocorticoids or experience severe side effects from glucocorticoids, other immunosuppressive agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ) may be tried, although clinical trials supporting this practice have not been published. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/1\">",
"      HARDY HL, TABERSHAW IR. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol 1946; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/2\">",
"      Fireman E, Haimsky E, Noiderfer M, et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/3\">",
"      Rossman MD, Kreider ME. Is chronic beryllium disease sarcoidosis of known etiology? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/4\">",
"      Kolanz ME. Introduction to beryllium: uses, regulatory history, and disease. Appl Occup Environ Hyg 2001; 16:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/5\">",
"      Taylor TP, Ding M, Ehler DS, et al. Beryllium in the environment: a review. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003; 38:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/6\">",
"      Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004; 363:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/7\">",
"      Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993; 35:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/8\">",
"      Kreiss K, Mroz MM, Zhen B, et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993; 148:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/9\">",
"      Kreiss K, Mroz MM, Newman LS, et al. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. Am J Ind Med 1996; 30:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/10\">",
"      Schuler CR, Kent MS, Deubner DC, et al. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med 2005; 47:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/11\">",
"      Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001; 74:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/12\">",
"      Stange AW, Hilmas DE, Furman FJ, Gatliffe TR. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg 2001; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/13\">",
"      Kelleher PC, Martyny JW, Mroz MM, et al. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001; 43:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/14\">",
"      Newman LS, Mroz MM, Maier LA, et al. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001; 43:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/15\">",
"      Sackett HM, Maier LA, Silveira LJ, et al. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J Occup Environ Med 2004; 46:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/16\">",
"      Stanton ML, Henneberger PK, Kent MS, et al. Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centers. J Occup Environ Med 2006; 48:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/17\">",
"      Cummings KJ, Deubner DC, Day GA, et al. Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers. Occup Environ Med 2007; 64:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/18\">",
"      Rosenman K, Hertzberg V, Rice C, et al. Chronic beryllium disease and sensitization at a beryllium processing facility. Environ Health Perspect 2005; 113:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/19\">",
"      Welch L, Ringen K, Bingham E, et al. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am J Ind Med 2004; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/20\">",
"      Stange AW, Furman FJ, Hilmas DE. Rocky Flats Beryllium Health Surveillance. Environ Health Perspect 1996; 104 Suppl 5:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/21\">",
"      Newman LS. Immunology, genetics, and epidemiology of beryllium disease. Chest 1996; 109:40S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/22\">",
"      Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996; 104 Suppl 5:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/23\">",
"      Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect 1996; 104 Suppl 5:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/24\">",
"      Maier LA. Clinical approach to chronic beryllium disease and other nonpneumoconiotic interstitial lung diseases. J Thorac Imaging 2002; 17:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/25\">",
"      Henneberger PK, Goe SK, Miller WE, et al. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg 2004; 1:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/26\">",
"      Maier LA, Martyny JW, Liang J, Rossman MD. Recent chronic beryllium disease in residents surrounding a beryllium facility. Am J Respir Crit Care Med 2008; 177:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/27\">",
"      CURTIS GH. Cutaneous hypersensitivity due to beryllium; a study of thirteen cases. AMA Arch Derm Syphilol 1951; 64:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/28\">",
"      Saltini C, Amicosante M, Franchi A, et al. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J 1998; 12:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/29\">",
"      Fontenot AP, Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol 2005; 26:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/30\">",
"      Hanifin JM, Epstein WL, Cline MJ. In vitro studies on granulomatous hypersensitivity to beryllium. J Invest Dermatol 1970; 55:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/31\">",
"      Kreiss K, Miller F, Newman LS, et al. Chronic beryllium disease--from the workplace to cellular immunology, molecular immunogenetics, and back. Clin Immunol Immunopathol 1994; 71:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/32\">",
"      Sawyer RT, Day BJ, Fadok VA, et al. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol 2004; 31:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/33\">",
"      Fontenot AP, Canavera SJ, Gharavi L, et al. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 2002; 110:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/34\">",
"      Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 1997; 158:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/35\">",
"      Tinkle SS, Newman LS. Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 1997; 156:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/36\">",
"      Bost TW, Riches DW, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. Am J Respir Cell Mol Biol 1994; 10:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/37\">",
"      Sawyer RT, Abraham JL, Daniloff E, Newman LS. Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas. J Occup Environ Med 2005; 47:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/38\">",
"      Sawyer RT, Dobis DR, Goldstein M, et al. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic Biol Med 2005; 38:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/39\">",
"      Marchand-Adam S, El Khatib A, Guillon F, et al. Short- and long-term response to corticosteroid therapy in chronic beryllium disease. Eur Respir J 2008; 32:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/40\">",
"      Dai S, Murphy GA, Crawford F, et al. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci U S A 2010; 107:7425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/41\">",
"      Maier LA. Genetic and exposure risks for chronic beryllium disease. Clin Chest Med 2002; 23:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/42\">",
"      Maier LA, McGrath DS, Sato H, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003; 171:6910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/43\">",
"      Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/44\">",
"      McCanlies EC, Ensey JS, Schuler CR, et al. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/45\">",
"      Weston A, Snyder J, McCanlies EC, et al. Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat Res 2005; 592:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/46\">",
"      Van Dyke MV, Martyny JW, Mroz MM, et al. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med 2011; 183:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/47\">",
"      Newman LS. To Be2+ or not to Be2+: immunogenetics and occupational exposure. Science 1993; 262:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/48\">",
"      McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol 2003; 157:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/49\">",
"      Maier LA, Sawyer RT, Bauer RA, et al. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 2001; 164:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/50\">",
"      Sato H, Silveira L, Fingerlin T, et al. TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization. J Allergy Clin Immunol 2007; 119:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/51\">",
"      McCanlies EC, Schuler CR, Kreiss K, et al. TNF-alpha polymorphisms in chronic beryllium disease and beryllium sensitization. J Occup Environ Med 2007; 49:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/52\">",
"      Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969; 46:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/53\">",
"      Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis 1992; 146:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/54\">",
"      Newman LS, Buschman DL, Newell JD Jr, Lynch DA. Beryllium disease: assessment with CT. Radiology 1994; 190:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/55\">",
"      Naccache JM, Marchand-Adam S, Kambouchner M, et al. Ground-glass computed tomography pattern in chronic beryllium disease: pathologic substratum and evolution. J Comput Assist Tomogr 2003; 27:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/56\">",
"      Handa T, Nagai S, Kitaichi M, et al. Long-term complications and prognosis of chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/57\">",
"      Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 1993; 148:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/58\">",
"      Newman LS. Beryllium disease and sarcoidosis: clinical and laboratory links. Sarcoidosis 1995; 12:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/59\">",
"      M&uuml;ller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006; 27:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/60\">",
"      Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992; 145:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/61\">",
"      Middleton DC, Lewin MD, Kowalski PJ, et al. The BeLPT: algorithms and implications. Am J Ind Med 2006; 49:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/62\">",
"      Middleton D, Kowalski P. Advances in identifying beryllium sensitization and disease. Int J Environ Res Public Health 2010; 7:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/63\">",
"      Saltini C, Winestock K, Kirby M, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989; 320:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/64\">",
"      Newman LS, Kreiss K, King TE Jr, et al. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989; 139:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/65\">",
"      Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance. Am J Ind Med 2004; 46:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/66\">",
"      Kreiss K, Mroz MM, Zhen B, et al. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997; 54:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/67\">",
"      Arjomandi M, Seward J, Gotway MB, et al. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. J Occup Environ Med 2010; 52:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/68\">",
"      Farris GM, Newman LS, Frome EL, et al. Detection of beryllium sensitivity using a flow cytometric lymphocyte proliferation test: the Immuno-Be-LPT. Toxicology 2000; 143:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/69\">",
"      Milovanova TN, Popma SH, Cherian S, et al. Flow cytometric test for beryllium sensitivity. Cytometry B Clin Cytom 2004; 60:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/70\">",
"      Maier LA, Kittle LA, Mroz MM, Newman LS. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am J Ind Med 2003; 43:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/71\">",
"      Pott GB, Palmer BE, Sullivan AK, et al. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol 2005; 115:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/72\">",
"      Fontenot AP, Palmer BE, Sullivan AK, et al. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J Clin Invest 2005; 115:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/73\">",
"      Amicosante M, Fontenot AP. T cell recognition in chronic beryllium disease. Clin Immunol 2006; 121:134.",
"     </a>",
"    </li>",
"    <li>",
"     Beryllium lymphocyte proliferation test (BeLPT): Bronchoalveolar lavage. file://www.nationaljewish.org/research/diagnostics/adx/requisitions/bal-belpt.aspx (Accessed on July 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/75\">",
"      Mroz MM, Kreiss K, Lezotte DC, et al. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991; 88:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/76\">",
"      Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/77\">",
"      Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest 2001; 120:109.",
"     </a>",
"    </li>",
"    <li>",
"     Newman, LS, Maier, LA. Beryllium Disease. In: Interstitial lung disease, 4, Schwarz, MI, King, TE (Eds), BC Decker, Hamilton, Ontario 2003. p.435.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/79\">",
"      Williams WJ. United Kingdom Beryllium Registry: mortality and autopsy study. Environ Health Perspect 1996; 104 Suppl 5:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/80\">",
"      Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990; 141:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/81\">",
"      Sood A. Current treatment of chronic beryllium disease. J Occup Environ Hyg 2009; 6:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/82\">",
"      Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 2004; 126:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/83\">",
"      FERRIS BG Jr. Chronic beryllium intoxication treated with corticosteroids and corticotropin. Am Rev Respir Dis 1962; 85:583.",
"     </a>",
"    </li>",
"    <li>",
"     Case studies in environmental medicine: Beryllium toxicity. file://www.atsdr.cdc.gov/csem/beryllium/index.html (Accessed on July 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/85\">",
"      Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/86\">",
"      M&uuml;ller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/87\">",
"      PEYTON MF, WORCESTER J. Exposure data and epidemiology of the beryllium case registry, 1958. AMA Arch Ind Health 1959; 19:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/88\">",
"      Mroz MM, Maier LA, Strand M, et al. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. Am J Ind Med 2009; 52:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/89\">",
"      Newman LS, Bobka C, Schumacher B, et al. Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med 1994; 150:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/90\">",
"      Beryllium and beryllium compounds. IARC Monogr Eval Carcinog Risks Hum 1993; 58:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/91\">",
"      MacMahon B. The epidemiological evidence on the carcinogenicity of beryllium in humans. J Occup Med 1994; 36:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/92\">",
"      Levy PS, Roth HD, Hwang PM, Powers TE. Beryllium and lung cancer: a reanalysis of a NIOSH cohort mortality study. Inhal Toxicol 2002; 14:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/93\">",
"      Hollins DM, McKinley MA, Williams C, et al. Beryllium and lung cancer: a weight of evidence evaluation of the toxicological and epidemiological literature. Crit Rev Toxicol 2009; 39 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/94\">",
"      Ward E, Okun A, Ruder A, et al. A mortality study of workers at seven beryllium processing plants. Am J Ind Med 1992; 22:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/95\">",
"      Madl AK, Unice K, Brown JL, et al. Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant. J Occup Environ Hyg 2007; 4:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/96\">",
"      Cullen MR, Kominsky JR, Rossman MD, et al. Chronic beryllium disease in a precious metal refinery. Clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am Rev Respir Dis 1987; 135:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/97\">",
"      Tinkle SS, Antonini JM, Rich BA, et al. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ Health Perspect 2003; 111:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/45/22234/abstract/98\">",
"      Day GA, Stefaniak AB, Weston A, Tinkle SS. Beryllium exposure: dermal and immunological considerations. Int Arch Occup Environ Health 2006; 79:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4367 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22234=[""].join("\n");
var outline_f21_45_22234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H271806246\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunologic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H621415692\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271805197\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271805890\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Beryllium lymphocyte proliferation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6629538\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6629594\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H286381505\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H271806695\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H271806688\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H286381525\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H621415872\">",
"      - Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H286381590\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271806681\">",
"      Other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271806535\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271806542\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271806246\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4367|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/11/29872\" title=\"picture 1\">",
"      Beryllium skin nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/12/26828\" title=\"table 1\">",
"      Laboratory findings in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/47/3835\" title=\"table 2\">",
"      ILD with BAL lymphocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=related_link\">",
"      Interpretation of lung biopsy results in interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_45_22235="Stress fracture site by sport";
var content_f21_45_22235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common sites of lower extremity stress fractures by sport",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sport",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stress fracture site(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baseball",
"       </td>",
"       <td>",
"        Tibia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basketball",
"       </td>",
"       <td>",
"        Anterior cortex of tibia, tarsal navicular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gymnastics",
"       </td>",
"       <td>",
"        Tibia, fibula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ice skating",
"       </td>",
"       <td>",
"        Distal fibula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Running",
"       </td>",
"       <td>",
"        Proximal tibial metaphysis, distal tibial metaphysis, fibula, tarsal navicular, midshaft of femur, distal femur, femoral neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soccer",
"       </td>",
"       <td>",
"        Patella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swimming",
"       </td>",
"       <td>",
"        Proximal tibia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volleyball",
"       </td>",
"       <td>",
"        Tibia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Yngve, DA. Stress fractures. In: Care of the young athlete, Sullivan, JA, Anderson, SJ (Eds), American Academy of Orthopedic Surgeons and American Academy of Pediatrics, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22235=[""].join("\n");
var outline_f21_45_22235=null;
var title_f21_45_22236="Hemorrhagic and thrombotic complications after ICH";
var content_f21_45_22236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemorrhagic and thromboembolic complications following anticoagulant-induced intracerebral hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of events",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Time after initial ICH (hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0 to 24",
"       </td>",
"       <td class=\"subtitle2\">",
"        25 to 48",
"       </td>",
"       <td class=\"subtitle2\">",
"        49 to 72",
"       </td>",
"       <td class=\"subtitle2\">",
"        73 to 120",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;120",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboembolic",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of events",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Time after restarting anticoagulation (hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0 to 24",
"       </td>",
"       <td class=\"subtitle2\">",
"        25 to 48",
"       </td>",
"       <td class=\"subtitle2\">",
"        49 to 72",
"       </td>",
"       <td class=\"subtitle2\">",
"        73 to 120",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;120",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboembolic",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICH: intracerebral hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hawryluk GW, Austin JW, Furlan JC, et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 2010; 8:1500.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22236=[""].join("\n");
var outline_f21_45_22236=null;
var title_f21_45_22237="Rx entero PVEII";
var content_f21_45_22237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of prosthetic valve endocarditis due to enterococci strains resistant to penicillin and susceptible to aminoglycoside* and vancomycin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       American Heart Association",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Adult (for patients with normal renal function)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Pediatric (not to exceed dose of normal adult)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Intrinsic penicillin resistance (Penicillin/ampicillin MIC &ge;32 &micro;g/mL)&bull;:",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       Intrinsic penicillin resistance (Penicillin/ampicillin MIC &ge;32 &micro;g/mL)&bull;:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Vancomycin&Delta; 30 mg/kg per 24 h IV in 2 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Gentamicin&loz;&sect; 3 mg/kg per 24 h IV or IM in 3 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"      <td class=\"indent1\">",
"       <p>",
"        Vancomycin&Delta; 40 mg/kg per 24 h IV in 2 or 3 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Gentamicin&loz;&sect; 3 mg/kg per 24h IV or IM in 3 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       &beta;-Lactamase producing:",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       &beta;-Lactamase producing:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       One of the following:",
"      </td>",
"      <td class=\"subtitle3_left\">",
"       One of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       <p>",
"        Ampicillin-sulbactam 12 g per 24 h IV in 4 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Vancomycin&Delta; 30 mg/kg per 24 h IV in 2 equally divided doses for 6 wks; not to exceed 2 g per 24 h unless concentrations in serum are inappropriately low",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Gentamicin&loz;&sect; 3 mg/kg per 24 h IV or IM in 3 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"      <td class=\"indent2\">",
"       <p>",
"        Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Vancomycin&Delta; 40 mg/kg per 24 h IV in 2 or 3 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Gentamicin&loz;&sect; 3 mg/kg per 24h IV or IM in 3 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * No high-level resistance to gentamicin and/or streptomycin.",
"     <br>",
"      &bull; Consultation with a specialist in infectious diseases recommended.",
"      <br>",
"       &Delta; Vancomycin therapy only recommended for patients unable to tolerate penicillins or intrinsic penicillin resistance. In adults vancomycin is dosed based on actual body weight. Vancomycin dose adjusted for peak serum concentrations (1 h after infusion) of 30-45 &micro;g/mL and trough concentration of 15-20 &micro;g/mL. The dose may need to be increased beyond 30 mg/kg actual body weight and frequency may need to be increased to 3 equally divided doses.",
"       <br>",
"        &loz; Renal function and serum gentamicin concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3-4 &micro;g/mL, trough &lt;1 &micro;g/mL.",
"        <br>",
"         &sect; Streptomycin may be used in lieu of gentamicin if isolate does not have high-level streptomycin resistance. In adults aminoglycosides are dosed based on ideal body weight. Streptomycin dose adults: 15 mg/kg per 24 h IV or IM in 2 equally divided doses; pediatrics: 20-30 mg/kg per 24 h IV or IM in 2 equally divided doses; dose adjusted for peak serum concentrations (1 h after infusion) of 20-35 &micro;g/mL and trough concentration of &lt;10 &micro;g/mL. In the setting of high-level gentamicin and streptomycin resistance, no aminoglycoside should be administered; treatment with &gt;6 weeks&nbsp;with a cell wall active agent is needed (see text). For E. faecalis, high dose ceftriaxone plus ampicillin is a therapeutic option (see text).",
"         <br>",
"          &yen; Intravenous form of amoxicillin-clavulanate is not available in US.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Baddour, LM, Wilson, WR, Bayer, AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association--executive summary: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:3167.",
"     <br>",
"      2. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"      <br>",
"       3. Liu, Catherine et al Clinical Practice guidelines by the Infectious Disease Society of America for the Treatment of Methicillin- Resistant Staphylococcus aureus Infections in Adults and Children. CID 2011; 52; 285-292.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22237=[""].join("\n");
var outline_f21_45_22237=null;
var title_f21_45_22238="Hepatic iron index";
var content_f21_45_22238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic iron index in hemochromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 434px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hepatic iron index (HII) in four groups of patients: normal controls, alcoholic liver disease, prefibrotic hemochromatosis, and fibrosis and cirrhosis caused by hemochromatosis. Among the patients with hemochromatosis, the open circles represent heterozygotes, and the closed circles represent homozygotes. The HII is calculated by dividing the hepatic iron concentration by the patient's age in years. All patients with homozygous hereditary hemochromatosis had an hepatic iron index greater than 2, a level not seen in the other patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bassett ML, Halliday JW, Powell LW. Hepatology 1986; 6:24.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22238=[""].join("\n");
var outline_f21_45_22238=null;
var title_f21_45_22239="Mechanisms of platelet activation with vascular injury";
var content_f21_45_22239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanisms of platelet activation with vascular injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 461px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endothelial cells normally release inhibitors of platelet aggregation, including nitric oxide and prostacyclin (PGI2) (Panel A). Disruption of the intact endothelium exposes the subendothelium and leads to the adherence of platelets. Once activated (Panel B), platelets degranulate, thereby releasing platelet aggregation agonists such as ADP and thromboxane A2. Degranulation also promotes surface thrombin generation and the recruitment of additional platelets, leading to thrombus formation.",
"    <div class=\"footnotes\">",
"     vWF: von Willebrand factor; GP: glycoprotein receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_45_22239=[""].join("\n");
var outline_f21_45_22239=null;
